Animal Production Methods
The method of polymerizing tetraploid embryos with embryonic stem cells enhances animal production efficiency and stability, addressing low birth rates and embryo damage issues in existing technologies, achieving 20-30% birth rates and enabling direct gene-edited animal production.
Patent Information
- Application Number
- JP2022553625
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-04-30
- Filing Date
- 2020-07-13
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-07-13
AI Technical Summary
Current methods for producing animals, particularly mice, using tetraploid compensation technology face low efficiency and stability issues, especially in generating transgenic mice, with birth rates often below 10% and difficulties in manipulating somatic cell nuclei, causing embryo damage.
A method involving the polymerization of tetraploid embryos with embryonic stem cells at the 2-cell stage, followed by transplantation into a pseudopregnant animal uterus, using a specific medium and fusion solution to enhance the efficiency and stability of animal production, particularly improving birth rates and overcoming limitations of existing gene editing methods.
The method significantly improves the birth rate of animals, especially mice, to 20-30%, while avoiding embryo damage, and allows for direct production of gene-edited animals with enhanced efficiency and stability, facilitating large-scale phenotypic studies and commercialization.
Smart Images

Figure 0007578306000014 
Figure 0007578306000015 
Figure 0007578306000016
Abstract
Description
[Technical field]
[0001] The present disclosure is in the field of biopharmaceuticals and relates to methods for producing animals. [Background technology]
[0002] Experimental animal disease models are essential research tools for the development of causes of human disease, pathogenesis mechanisms, preventive and therapeutic techniques and therapeutic drugs. Common experimental animals include mice, rats, guinea pigs, hamsters, rabbits, dogs, monkeys, pigs and fish. However, there are still many differences in gene and protein sequences between humans and animals, and many human proteins cannot combine with animal homologous proteins to produce biological activity, and many clinical trial results are inconsistent with the results of animal experiments.
[0003] With the continuous development and maturity of genetic engineering technology, human cells or genes can be substituted or replaced with endogenous homologous cells or genes of animals to establish biological systems or disease models closer to humans, and the establishment of humanized experimental animal models has already provided important tools for clinically new therapeutic methods or means. Here, the genetic humanized animal model is that the homologous genes of animals can be substituted with normal or mutant genes of humans using genetic engineering technology to establish normal or mutant genes closer to humans in the animal body. The presence of human gene fragments allows proteins containing human functions to be expressed or partially expressed in the animal body, thereby greatly reducing the difference between clinical experiments between humans and animals, and providing the possibility of conducting drug screening at the animal level.
[0004] Like SARS coronavirus, 2019-nCoV has angiotensin-converting enzyme 2 (ACE2) as an important target for infecting humans, where 2019-nCoV can infect various mammals, such as monkeys, pigs, rabbits, ferrets, orangutans, in addition to humans, but excluding mice and rats. Monkeys, pigs, rabbits, etc. are used as animal models for drug screening by infecting them with 2019-nCoV, and because they have a long growth cycle and a large body size, they are difficult to manipulate in large quantities, while mouse models, which are easy to manipulate in large quantities, are difficult to infect with 2019-nCoV.
[0005] A tetraploid is an organism or cell that contains four times the minimum number of chromosomes in a cell, i.e., has four complete sets of chromosomes. Under natural conditions, the incidence of mammalian tetraploid embryos is very low and they generally fail to develop normally into individual individuals.
[0006] A certain number of embryonic stem (ES) cells are chimerized with tetraploid embryos, and during the development of the chimeras, the ES cells and tetraploid embryos are not randomly distributed; that is, the tetraploid embryos are only involved in the formation of extraembryonic tissues such as yolk sac endoderm and placental trophoblast cells (e.g., chorionic ectoderm, trophoblast cells, etc.), while the ES cells are widely involved in the generation of embryoid bodies, allantois, amnion, yolk sac mesoderm and chorionic mesoderm, but are not involved in the generation of yolk sac endoderm and placental trophoblast cell lineages; that is, the developmental abilities of the two are complementary; this phenomenon is called tetraploid complementation technology.
[0007] The animal individuals cloned by this technology are entirely developed from ES cells and are called ES animals. After the cloned embryos produced by the cell nuclear transfer method are transferred into surrogate mothers, the birth rate of fetuses is very low at 1-2%. By using the tetraploid compensation technique, that is, by injecting ESC cell lines into tetraploid embryo vectors at the vesicle stage, the birth rate of fetuses can be increased to 20-30%, which significantly improves the efficiency of animal cloning. In recent years, many scientists at home and abroad have been studying this technology diligently and obtained many creative research results. The animal models generated by the tetraploid compensation technique are very commonly used, such as identifying lineage-specific gene functions, analyzing gene functions in extraembryonic tissues and embryonic tissues, identifying spontaneous and involuntary gene functions in cells, distinguishing major and minor defects, and facilitating phenotype analysis. The application of embryo chimeras is not limited to the study of early embryo development, but can also be applied to the study of postnatal fetal development and physical functions. When chimeras are used in combination with molecular tools, these molecular tools can modify genetic activity in a time- and lineage-specific manner in cells, providing convenience for precise, detailed, and large-scale analysis of gene function. Genetic activity (Nagy 2000) can be changed or gene function can be regulated by conditionally changing gene expression. Currently, evaluation of the developmental potential of ES cells mainly focuses on studying cell differentiation in vitro and analyzing the transcriptional activity of molecular markers that reflect cell pluripotency. One unique feature of embryonic chimeras is that foreign cells can be chimerized into embryos, and the cells can be fully excited to differentiate during the development of the embryo. The cells undergo a comprehensive cell lineage test, which can better reveal the true degree of pluripotency. Chimeras are the most comprehensive, most rigorous, and important tool in in vivo cell evaluation for predicting the pluripotency of mammalian animals. Summary of the Invention
[0008] In some embodiments, the present disclosure provides methods of manufacture that can improve the birth rate of animals.
[0009] In some embodiments, the present disclosure provides methods for animal tetraploid embryo complementation.
[0010] In some embodiments, the disclosure provides a method for producing an animal comprising polymerizing a tetraploid embryo with an embryonic stem cell to form a new reconstituted embryo or a chimeric embryo, wherein the tetraploid embryo is a tetraploid embryo at the 2-cell stage.
[0011] In some embodiments, the embryonic stem cells are embryonic stem cells that have been passaged no more than p15 generations.
[0012] In some embodiments, the embryonic stem cells are passage p12-p15 generation embryonic stem cells.
[0013] In some embodiments, the method uses tetraploid compensation or tetraploid embryo complementation.
[0014] In some embodiments, the method includes the steps of: (1) obtaining a 2-cell embryo of an animal; (2) placing the 2-cell embryo described in step (1) in a fusion solution and fusing to obtain a tetraploid embryo; (3) placing the tetraploid embryo in step (2) in a culture medium and culturing it; (4) polymerizing the tetraploid embryo developed to the 2-cell stage in step (3) with embryonic stem cells to form a chimeric embryo; and (5) obtaining an animal by implanting the chimeric embryo in step (4) into a pseudopregnant animal uterus and allowing the embryo to develop to full-term pregnancy.
[0015] In some embodiments, the incubation time in step (3) is 8-24 hours.
[0016] In some embodiments, the medium in step (3) is KSOM medium.
[0017] In some embodiments, the non-human animal from which the recipient embryo is derived may be any animal other than a human, such as a pig, rat, mouse, hamster, rabbit, pig, cow, deer, sheep, goat, chicken, cat, horse, dog, orangutan, monkey, etc. At the same time, the mammal used as the original source of the cells transplanted into the recipient may be a human or non-human mammal, such as a pig, rat, mouse, cow, sheep, goat, horse, dog, baboon, chimpanzee, gorilla, orangutan, monkey, marmoset, bonobo, etc.
[0018] In some embodiments, the animal is a mammal.
[0019] In some embodiments, the animal is a non-human mammal.
[0020] In some embodiments, the animal is selected from a pig, a rat, a mouse, a hamster, a rabbit, a pig, a cow, a deer, a sheep, a goat, a chicken, a cat, a horse, a dog, an orangutan, and a monkey.
[0021] In some embodiments, the animal is selected from a mouse. In some embodiments, the animal is selected from an adult mouse. In some embodiments, the animal is selected from a fetal mouse.
[0022] According to conventional techniques, the current technology for producing animals is difficult to meet the requirements of practical application. For example, in the production of mice, early studies showed that mouse tetraploid embryos could not develop normally, and could only form the trophoblast and extraembryonic endoderm of the placenta (Tarkowski et al., 1977), and embryonic stem cells could form the entire fetus itself, as well as the mesoderm of the yolk sac, the amnion, the allantois, the umbilical cord, etc., but had a very limited ability to form the trophoblast and yolk sac endoderm (Beddington et al., 1989). Tetraploid compensation technology was created based on such a perfect complementary relationship, and in the most extreme case, when using embryonic stem cells of the highest quality pure genetic background, the birth rate of fetuses can reach up to 15%, but these mice all died immediately after birth (Nagy et al., 1990).
[0023] Later, people found that chimeric embryos obtained using early passage F1 genetic background embryonic stem cells could develop to term and live to adulthood, but with only a 3.8% efficiency (Nagy et al., 1993). Later, it was reported that F1 embryonic stem cells after gene targeting could reach a survival rate of 5-15% after recloning, but the survival rate of mice produced with pure embryonic stem cells was still only 0-1.4% (Eggan et al., 2001). In 2006, Guy S Eakin et al. published a method to generate mice using the aggregation of embryonic stem cells with diploids or tetraploids (Eakin and Hadjantonakis, 2006). Other method publications include (Gertsenstein, 2015; Kang and Gao, 2015; Li et al., 2015; Shinozawa et al., 2006; Tanaka et al., 2009; Wen et al., 2014; Yamaguchi et al., 2018; Zhao et al., 2009; Zhao et al., 2010). In 2009, Michal J. Boland et al. reported that the birth rate of mice generated from mouse induced pluripotent stem cells using tetraploid compensation technology was 0-7%, and most were 0% (Boland et al., 2009). Among them, the birth rate published by Zhou Qi in the international journal NATURE was also only 0-3% (Zhao et al., 2009). Through screening of a large number of cell lines, technical improvements, and recloning of F1 background embryonic stem cells, the efficiency of mouse production through tetraploid compensation technology has been improved. However, F1 is not an ideal genetic background, and the technology still has difficulty meeting the requirements for practical application. In particular, it is still very difficult to directly produce genetically modified mice through tetraploid compensation technology using pure embryonic stem cells.
[0024] In some embodiments, the disclosure provides a method for producing a gene-edited animal using the method for producing the animal. In some embodiments, the animal is a genetically humanized animal. In some embodiments, the animal is a mammal. In some embodiments, the animal is a non-human mammal. In some embodiments, the animal is selected from a pig, a rat, a mouse, a hamster, a rabbit, a pig, a cow, a deer, a sheep, a goat, a chicken, a cat, a horse, a dog, an orangutan, and a monkey. In some embodiments, the rodent animal is a mouse. In some embodiments, the animal is an adult mouse. In some embodiments, the animal is a fetal mouse.
[0025] There are several methods for obtaining gene-edited mice, including blastocyst injection of pluripotent stem cells, direct editing by fertilized egg injection, somatic cell nuclear transfer, and tetraploid compensation technology. Among them, blastocyst injection of pluripotent stem cells requires obtaining chimeric mice transmitted through the germ line and then performing subculturing to obtain homozygous mice, which takes more than five months. Fertilized egg injection is generally used for gene knockout editing, and has limited gene editing policies and is technically difficult to operate, and the mice born afterwards must be identified, so the desired mice cannot always be obtained directly. Both somatic cell nuclear transfer and tetraploid compensation technology can directly obtain homozygous gene-edited mice, but the survival rates of the two methods are low, less than 10%, and generally around 1%. In addition, the difficulty of moving the somatic cell nucleus is high, microinjection causes great damage to the embryo, and the tetraploid compensation method does not cause direct damage to the embryo. Regarding directly obtaining gene-edited mice, the tetraploid compensation technology is simpler and more efficient than somatic cell nuclear transfer manipulation, the time required to obtain gene-edited animals is shorter, and it is relatively easy to perform gene editing on pluripotent stem cells.
[0026] In some embodiments, a method for producing a genetic mouse is provided, the method including the steps of: (1) obtaining a mouse 2-cell embryo; (2) placing the 2-cell embryo described in step (1) in a fusion solution and fusing to obtain a tetraploid embryo; (3) placing the tetraploid embryo in step (2) in a culture medium and culturing it; (4) polymerizing the tetraploid embryo developed to the 2-cell stage in step (3) with embryonic stem cells to form a chimeric embryo; and (5) implanting the chimeric embryo in step (4) into the uterus of a pseudopregnant mouse and allowing the embryo to develop into a full-term pregnancy, thereby obtaining a gene-edited mouse.
[0027] In some embodiments, the method includes polymerizing the embryonic stem cells and the tetraploid embryo to form a new reconstituted embryo, where the embryonic stem cells can be general embryonic stem cells or gene-edited embryonic stem cells, such as, but not limited to, genetically humanized animal embryonic stem cells.
[0028] In some embodiments, a method for producing a chimeric animal embryo is provided, comprising polymerizing a tetraploid embryo with an embryonic stem cell to form a new reconstituted embryo or a chimeric embryo, wherein the tetraploid embryo is a tetraploid embryo at the 2-cell stage.
[0029] In some embodiments, the method uses tetraploid compensation or tetraploid embryo complementation.
[0030] In some embodiments, the method includes the steps of (1) obtaining a 2-cell embryo of an animal, (2) placing the 2-cell embryo described in step (1) in a fusion solution and fusing it to obtain a tetraploid embryo, (3) placing the tetraploid embryo in step (2) in a culture medium and culturing it, and (4) polymerizing the tetraploid embryo developed to the 2-cell stage with an embryonic stem cell in step (3) to form a chimeric embryo. In some embodiments, the culture time in step (3) is 8-24 hours. In some embodiments, the culture medium in step (3) is KSOM medium. In some embodiments, the animal is a mammal. In some embodiments, the animal is a non-human mammal. In some embodiments, the animal is selected from pigs, rats, mice, hamsters, rabbits, pigs, cows, deer, sheep, goats, chickens, cats, horses, dogs, orangutans, and monkeys. In some embodiments, the animal is selected from mice. In some embodiments, the animal is selected from adult mice. In some embodiments, the animal is selected from fetal mice.
[0031] In some embodiments, the method includes polymerizing tetraploid embryos developed at the 2-cell stage with embryonic stem cells to obtain chimeric embryos.The inventors further unexpectedly discovered that by using the polymerization of tetraploid embryos at the 2-cell stage with embryonic stem cells, the problems of low efficiency stability of mouse production using tetraploid compensation technology and low efficiency of embryonic stem cells from pure line mice can be greatly improved, the birth rate of mice can be qualitatively improved, and the embryo can be closer to normal embryo transfer, while at the same time overcoming the limitations of the current state-of-the-art gene editing method Cas9, and embryos and adult mice can be directly produced from stem cells for phenotypic research, saving a large amount of time, manpower and materials required for mouse breeding, thoroughly solving the practicality problem of producing transgenic mice with tetraploid compensation technology, and reaching the level of commercialization.
[0032] In some embodiments, in the method for producing an animal, a composition containing ingredients including mannitol, MgSO4, CaCl2, and bovine serum albumin is used, and the mass ratio of the mannitol, MgSO4, CaCl2, and bovine serum albumin is 9-53:0.015-0.241:0.013-0.23:0.01-5.
[0033] In some embodiments, the method uses a composition containing components of mannitol, MgSO4, CaCl2, and bovine serum albumin, and the mass ratio of the mannitol, MgSO4, CaCl2, and bovine serum albumin is 9-53:0.015-0.241:0.013-0.23:0.01-5.
[0034] In some embodiments, the mass ratio of mannitol, MgSO4, CaCl2, and bovine serum albumin in the composition is 18-52:0.018-0.241:0.016-0.23:0.01-4.
[0035] In some embodiments, the mass ratio of mannitol, MgSO4, CaCl2, and bovine serum albumin in the composition is 27-52:0.018-0.12:0.016-0.1:1-3.5.
[0036] In some embodiments, the composition comprises the following components: mannitol 0.05-0.29M, MgSO4 0.12-2mM, CaCl2 0.12-2mM, bovine serum albumin 0.01-5mg / mL.
[0037] In some embodiments, the composition comprises the following components: mannitol 0.1-0.28 M, MgSO4 0.15-2 mM, CaCl2 0.15-2 mM, bovine serum albumin 0.01-4 mg / mL.
[0038] In some embodiments, the composition comprises the following ingredients: mannitol 0.15-0.28M, MgSO4 0.15-1 mM, CaCl2 0.15-1 mM, bovine serum albumin 1-3.5 mg / mL.
[0039] In some embodiments, the composition comprises the following ingredients: mannitol 0.18-0.28 M, MgSO4 0.15-0.5 mM, CaCl2 0.15-0.5 mM, bovine serum albumin 2-3.5 mg / mL.
[0040] In some embodiments, the composition comprises the following ingredients: mannitol 0.2-0.28 M, MgSO4 0.15-0.3 mM, CaCl2 0.15-0.3 mM, bovine serum albumin 2-3 mg / mL.
[0041] In some embodiments, the composition comprises the following ingredients: mannitol 0.27 M, MgSO4 0.2 mM, CaCl2 0.2 mM, bovine serum albumin 3 mg / mL.
[0042] In some embodiments, the composition may be prepared as a mother liquor that is then made into a working solution of the desired concentration.
[0043] In some embodiments, the composition may be a working solution and may be used as is without the need for preparation.
[0044] In some embodiments, the disclosure provides an application of the composition in producing a gene-edited animal embryonic cell or a gene-edited animal.
[0045] In some embodiments, the compositions are used to produce a tetraploid embryo of an animal.
[0046] In some embodiments, the method further comprises the steps of: 2+ and Ca 2+ A fusion solution containing Mg was used, and the fusion solution had an increased concentration. 2+ and Ca 2+ or the fusion liquid has Mg 2+ and Ca 2+ The concentrations of are 0.12-2 mM and 0.12-2 mM, respectively.
[0047] In some embodiments, the concentrations of mannitol and bovine serum albumin in the fusion solution are 0.05-0.29 M and 0.01-5 mg / mL, respectively.
[0048] In some embodiments, the Mg 2+ and Ca 2+ are derived from MgSO4 and CaCl2, respectively.
[0049] In some embodiments, the fusion fluid is used to produce tetraploid embryos.
[0050] At present, the methods for obtaining tetraploids include biological, chemical and physical methods. Injecting two diploid embryonic cell nuclei into the cytoplasm of one 1-cell stage embryonic cell by micromanipulation places high demands on the operation technique, and at the same time, micromanipulation causes great damage to the embryo. Using cytochalasin B or colchicine to inhibit the division of blastomere cells to produce tetraploids has a negative effect on embryo development, and may even delay or prevent embryo development. In addition, Sendai virus, polyethylene glycol, direct current shock and other methods can be used to fuse cells, and Sendai virus is pathogenic and polyethylene glycol remains toxic, whereas electrofusion only produces reversible electroporation in a short time, eliminating the toxicity of chemical reagents and the pathogenicity of viruses, and is the most common and most efficient method for producing tetraploid embryos. However, the conventional tetraploid compensation technology has problems such as the embryo electrofusion efficiency not reaching 100%, the efficiency stability of producing mice is low, and the efficiency of embryonic stem cells from pure line mice is low. During the course of research, the inventors unexpectedly discovered that the fusion efficiency can be improved from 80-90% to 100% when using the improved electrofusion solution of the present disclosure, which is of great practical significance.
[0051] In some embodiments, the disclosure provides an animal produced by the method.
[0052] In some embodiments, the animal is a mammal. In some embodiments, the animal is a non-human mammal. In some embodiments, the animal is selected from a pig, a rat, a mouse, a hamster, a rabbit, a pig, a cow, a deer, a sheep, a goat, a chicken, a cat, a horse, a dog, an orangutan, or a monkey. In some embodiments, the animal is selected from a mouse. In some embodiments, the animal is selected from an adult mouse. In some embodiments, the animal is selected from a fetal mouse. In some embodiments, the animal is selected from a gene-edited animal. In some embodiments, the animal is selected from a genetically humanized animal. In some embodiments, the gene is ACE2.
[0053] In some embodiments, the present disclosure provides a method for the preparation of a medicament for the treatment of osteoporosis, comprising administering to the patient a sufficient amount of mannitol, bovine serum albumin, Mg 2+ and Ca 2+ The fusion liquid contains an increased concentration of Mg. 2+ and Ca 2+ or the fusion liquid has Mg 2+ and Ca 2+ The concentrations of are 0.12-2 mM and 0.12-2 mM, respectively.
[0054] In some embodiments, the concentrations of mannitol and bovine serum albumin in the fusion liquid are 0.05-0.29 M and 0.01-5 mg / mL, respectively.
[0055] In some embodiments, the Mg 2+ and Ca 2+ are derived from MgSO4 and CaCl2, respectively.
[0056] In some embodiments, the method for producing the animal uses the fusion fluid.
[0057] In some embodiments, the disclosure provides tissues, body fluids, cells, cell nuclei, and fragments or extracts thereof of a gene-edited animal or its progeny, the animal being constructed by the above method. In some embodiments, the animal is a mammal. In some embodiments, the animal is a non-human mammal. In some embodiments, the animal is selected from pigs, rats, mice, hamsters, rabbits, pigs, cows, deer, sheep, goats, chickens, cats, horses, dogs, orangutans, and monkeys. In some embodiments, the animal is selected from mice. In some embodiments, the animal is selected from adult mice. In some embodiments, the animal is selected from fetal mice.
[0058] It has been reported in the literature that human ACE2 and mouse ACE2 have certain differences in gene sequences, and therefore, after viral infection, human ACE2 is more susceptible to SARS-CoV and has more obvious pathological symptoms than mouse ACE2.Current clinical research urgently needs better animal models.
[0059] It was confirmed that hACE2 transgenic mice can be infected with 2019-nCoV and show typical pathogenic characteristics in lung tissue (https: / / www.biorxiv.org / content / 10.1101 / 2020.02.07.939389v3#disqus_thread). hACE2 transgenic mice are a mouse model of systemic overexpression of hACE2 and cannot simulate the spatiotemporal tissue expression characteristics of ACE2.
[0060] In some embodiments, the present disclosure provides a method for expressing humanized ACE2 at the mouse ACE2 site to mass-produce 2019-nCoV-susceptible mouse humanized ACE2 animal models for applications such as drug screening and disease research against 2019-nCoV.
[0061] In some embodiments, the disclosure provides specific RNA fragment sequences.
[0062] In some embodiments, the RNA fragment sequence is an isolated RNA fragment sequence.
[0063] In some embodiments, the present disclosure provides specific sgRNA sequences targeting the ACE2 gene.
[0064] In some embodiments, the sgRNA sequence is an isolated sgRNA sequence.In some embodiments, the present disclosure provides a specific targeting vector that targets the ACE2 gene.
[0065] In some embodiments, the targeting vector is an isolated targeting vector.
[0066] In some embodiments, the present disclosure provides ACE2 gene humanized cell lines.
[0067] In some embodiments, the present disclosure provides methods for producing ACE2 gene humanized cell lines.
[0068] In some embodiments, the present disclosure provides an ACE2 genetically humanized animal.
[0069] In some embodiments, the present disclosure provides methods for producing genetically humanized animals.
[0070] In some embodiments, the present disclosure provides an ACE2 gene humanized mouse embryonic stem cell model.
[0071] In some embodiments, the disclosure provides primer combinations comprising an upstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:19, and a downstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:20.
[0072] In some embodiments, the primer is an isolated primer.
[0073] In some embodiments, the primer combination further comprises an upstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:21, and a downstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:22.
[0074] In some embodiments, the primer is an isolated primer.
[0075] In some embodiments, the primer combination further comprises an upstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:23, and a downstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:24.
[0076] In some embodiments, the primer is an isolated primer.
[0077] In some embodiments, the primer combination further comprises an upstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:25, and a downstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:26.
[0078] In some embodiments, the primer is an isolated primer.
[0079] In some embodiments, the present disclosure provides applications of said primer combinations in the manufacture of cell lines or cell systems or non-human animals.
[0080] In some embodiments, the cell is an isolated cell.
[0081] In some embodiments, the animal is a mammal. In some embodiments, the animal is selected from a pig, rat, mouse, hamster, rabbit, pig, cow, deer, sheep, goat, chicken, cat, horse, dog, orangutan, or monkey. In some embodiments, the mammal is a rodent. In some embodiments, the animal is a mouse. In some embodiments, the animal is selected from an adult mouse. In some embodiments, the animal is selected from a fetal mouse.
[0082] In some embodiments, the animal is a genetically humanized animal.
[0083] In some embodiments, the gene is ACE2.
[0084] In some embodiments, the present disclosure provides an application of the primer combination in the production of a targeting vector.
[0085] In some embodiments, the present disclosure provides a targeting vector comprising a 5' homology arm sequence, a human ACE2 gene fragment and an SV40 polyA sequence linked together, wherein the 5' homology arm has homology to a 5' target sequence at the target genomic locus.
[0086] In some embodiments, the targeting vector is an isolated targeting vector.
[0087] In some embodiments, the targeting vector uses the primer combination to link the 5' homology arm sequence, the human-derived ACE2 gene fragment, and the SV40 polyA sequence.
[0088] In some embodiments, the targeting vector is used to insert the CDS sequence of the human ACE2 gene into the promoter and 5'UTR region sequence of the animal gene, and then drive expression of the human gene of interest using the animal gene of interest promoter.
[0089] In some embodiments, the 5' homology arm sequence has at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence shown in SEQ ID NO:15.
[0090] In some embodiments, the CDS sequence of the ACE2 gene has at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence shown in SEQ ID NO:12.
[0091] In some embodiments, the SV40 polyA sequence has at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence shown in SEQ ID NO:14.
[0092] In some embodiments, the SV40 polyA sequence is located after the CDS sequence.
[0093] In some embodiments, the targeting vector further comprises a 3' homology arm, the 3' homology arm having homology to a 3' target sequence at the genomic locus of interest.
[0094] In some embodiments, the targeting vector further comprises a screening marker PGK-Puro having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence shown in SEQ ID NO:17.
[0095] In some embodiments, the targeting vector further comprises an Frt sequence having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:18.
[0096] In some embodiments, the linking order of each sequence fragment of the targeting vector is 5' homology arm sequence, human-derived ACE2 gene fragment, SV40 polyA sequence, frt sequence, PGK-Puro sequence, frt sequence, and 3' homology arm sequence.
[0097] In some embodiments, the animal is a mammal. In some embodiments, the animal is selected from a pig, rat, mouse, hamster, rabbit, pig, cow, deer, sheep, goat, chicken, cat, horse, dog, orangutan, or monkey. In some embodiments, the mammal is a rodent. In some embodiments, the animal is a mouse. In some embodiments, the animal is selected from an adult mouse. In some embodiments, the animal is selected from a fetal mouse.
[0098] In some embodiments, the animal is a genetically humanized animal.
[0099] In some embodiments, the gene is ACE2.
[0100] In some embodiments, the present disclosure provides an application of the targeting vector in the preparation of a genetic humanized animal model, which is a hACE2 mouse model in which the original mouse ACE2 site is specifically expressed, and can simulate the expression characteristics of the original mACE2, has tissue specificity, and can more closely simulate the pathogenesis of human infection with 2019-nCoV.
[0101] In some embodiments, the animal is a mammal. In some embodiments, the animal is selected from a pig, rat, mouse, hamster, rabbit, pig, cow, deer, sheep, goat, chicken, cat, horse, dog, orangutan, or monkey. In some embodiments, the mammal is a rodent. In some embodiments, the animal is a mouse. In some embodiments, the animal is selected from an adult mouse. In some embodiments, the animal is selected from a fetal mouse.
[0102] In some embodiments, the animal is a genetically humanized animal.
[0103] In some embodiments, the gene is ACE2.
[0104] In some embodiments, the present disclosure provides a method for producing the targeting vector, comprising the step of PCR amplifying the product fragments 5' homology arm, human ACE2 CDS and SV40 polyA into a continuous fragment 5arm-hACE-SV40 by bridging PCR.
[0105] In some embodiments, the PCR reaction system comprises about 25 μL of 2×Phanta Max Buffer, about 1 μL of dNTP Mix, about 2 μL of 10 μM upstream primer, about 2 μL of 10 μM downstream primer, about 1 μL of DNA Polymerase, about 20-200 ng each of template chain 5′ homology arm, human ACE2 CDS, and SV40 polyA fragment, and supplemented with HO to 50 μL, with PCR amplification reaction conditions starting at about 62-68° C. and decreasing by about 0.2-0.5° C. each cycle.
[0106] In some embodiments, the primers used to amplify the 5' homology arm fragment comprise an upstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence shown in SEQ ID NO:19, and a downstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence shown in SEQ ID NO:20.
[0107] In some embodiments, the primer is an isolated primer.
[0108] In some embodiments, the primers used to amplify the human ACE2 gene fragment comprise an upstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:21, and a downstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:22.
[0109] In some embodiments, the primer is an isolated primer.
[0110] In some embodiments, the primers used for the SV40 polyA sequence include an upstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:23, and a downstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:24.
[0111] In some embodiments, the primer is an isolated primer.
[0112] In some embodiments, the method further comprises the step of performing AgeI+MluI double digestion on the 5arm-hACE-SV40 fragment and AscI+HindIII double digestion on the 3' homology arm fragment, followed by ligation to obtain a targeting vector.
[0113] In some embodiments, the primers used for the 3' homology arm fragment comprise an upstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence shown in SEQ ID NO:25, and a downstream primer having at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence shown in SEQ ID NO:26.
[0114] In some embodiments, the primer is an isolated primer.
[0115] In some embodiments, the present disclosure provides methods for producing humanized animal cell lines using said primer combinations.
[0116] In some embodiments, the method comprises using the targeting vector.
[0117] In some embodiments, the method comprises introducing the human gene of interest into an animal cell, such that the gene of interest expresses the CDS of the human gene of interest in the animal cell.
[0118] In some embodiments, the gene of interest is ACE2.
[0119] In some embodiments, the animal is a mammal. In some embodiments, the animal is a rodent. In some embodiments, the animal is a mouse.
[0120] In some embodiments, the cells are embryonic stem cells.
[0121] In some embodiments, the production method includes the steps of (1) producing the targeting vector; (2) introducing the produced targeting vector and a vector linked to an sgRNA into an animal-derived embryonic stem cell; and (3) culturing the embryonic stem cell in step (2) into a clone.
[0122] In some embodiments, the sgRNA comprises an sgRNA that has at least 85%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identity to the sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.
[0123] In some embodiments, the animal is a mammal. In some embodiments, the animal is selected from a pig, rat, mouse, hamster, rabbit, pig, cow, deer, sheep, goat, chicken, cat, horse, dog, orangutan, or monkey. In some embodiments, the mammal is a rodent. In some embodiments, the rodent is a mouse. In some embodiments, the animal is selected from an adult mouse. In some embodiments, the animal is selected from a fetal mouse. In some embodiments, the animal is a genetically humanized animal.
[0124] In some embodiments, the gene is ACE2.
[0125] In some embodiments, the present disclosure provides an ACE2 gene humanized animal cell line or cell line produced by the above method.
[0126] In some embodiments, the cells are humanized mouse embryonic stem cells.
[0127] In some embodiments, the present disclosure provides a method for producing a non-human animal comprising reciting the above primer combinations.
[0128] In some embodiments, the manufacturing method uses the targeting vector.
[0129] In some embodiments, the method comprises injecting the cells into an animal.
[0130] In some embodiments, the animal is a mammal. In some embodiments, the animal is selected from a pig, rat, mouse, hamster, rabbit, pig, cow, deer, sheep, goat, chicken, cat, horse, dog, orangutan, or monkey. In some embodiments, the mammal is a rodent. In some embodiments, the rodent is a mouse. In some embodiments, the animal is selected from an adult mouse. In some embodiments, the animal is selected from a fetal mouse. In some embodiments, the animal is a genetically humanized animal.
[0131] In some embodiments, the gene is ACE2.
[0132] In some embodiments, the disclosure provides a non-human animal produced by the above method.
[0133] In some embodiments, the animal is a mammal. In some embodiments, the animal is selected from a pig, rat, mouse, hamster, rabbit, pig, cow, deer, sheep, goat, chicken, cat, horse, dog, orangutan, or monkey. In some embodiments, the mammal is a rodent. In some embodiments, the rodent is a mouse. In some embodiments, the animal is selected from an adult mouse. In some embodiments, the animal is selected from a fetal mouse. In some embodiments, the animal is a genetically humanized animal.
[0134] In some embodiments, the gene is ACE2.
[0135] In some embodiments, the humanized mouse embryonic stem cells comprise a human ACE2 gene, and the humanized mouse embryonic stem cells can express full-length human ACE2 protein after being specifically differentiated or prepared into a mouse model, while the expression of endogenous ACE2 protein is reduced or eliminated.
[0136] In some embodiments, the disclosure provides tissues, body fluids, cells, and homogenates or extracts thereof of a humanized mouse or its progeny, wherein the humanized mouse is produced by the above-described method.
[0137] In some embodiments, the present disclosure provides for the use of the humanized animal model obtained by the above production method or its progeny in the production of human antibodies, or in model systems for pharmacology, immunology, microbiology and medical research, or in the production and use of animal experimental disease models, in pathogenesis research and / or development of new diagnostic and / or therapeutic strategies, or in the screening, validation, evaluation or study of ACE2 gene function, ACE2 antibodies, drugs against ACE2 targets, and efficacy research. [Brief description of the drawings]
[0138] [Figure 1] 1 is a plasmid map of pX330. [Diagram 2] FIG. 1 shows the results of constructing and sequencing pX330-sgRNA1. [Diagram 3] FIG. 1 shows the results of constructing and sequencing pX330-sgRNA2. [Figure 4] This shows the results of verifying the cleavage efficiency of pX330-sgRNA1-3. [Diagram 5] FIG. 1 shows the results of constructing and sequencing pX330-sgRNA3. [Figure 6] FIG. 1 is a schematic diagram of the targeting scheme of humanized ACE2. [Figure 7] This is the sequencing result information of the humanized ACE2 targeting vector. [Figure 8] FIG. 1 shows PCR identification of three ligated fragments in Comparative Example 1. [Figure 9] FIG. 1 shows the results of PCR identification of humanized ACE2 mouse embryonic stem cell genotype. [Figure 10] FIG. 1 shows the results of PCR identification of humanized ACE2 mouse embryonic stem cell genotype after deletion of PGK-Puro. [Figure 11] FIG. 1 is a schematic diagram of the humanized ACE2 gene. [Figure 12] 1 is an image of a humanized ACE2 gene-modified mouse generated in Example 8. [Figure 13] The expression of hACE2 in humanized ACE2 mice was measured by qPCR, and the results show that humanized ACE2 mouse tissues specifically express hACE2, whereas wild-type mice do not express hACE2. [Figure 14] The expression of mACE2 in humanized ACE2 mice was measured by qPCR, showing that the expression of mACE2 in hACE2 mice was lost. [Figure 15] Western blotting experiments measured the expression of hACE2 protein in the intestinal tissues of hACE2 mice and wild-type ACE2 mice, showing that hACE2 mice expressed hACE2 protein at the protein level. [Figure 16] 1 is a flowchart for producing mice in Example 10, Test Example 1, Example 11, and Test Example 2. [Figure 17] 1 is a flowchart for producing mice in Example 12, Test Example 3, Example 13, and Test Example 4. [Figure 18] FIG. 13 is a graph showing the birth rates of mice in Examples 10-13. [Figure 19] FIG. 1 is a graph showing the birth rates of mice in Test Example 1-4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0139] The technical solutions of the present disclosure are further described below through specific examples, and the specific examples do not limit the protection scope of the present disclosure. Some non-essential modifications and adjustments made by others based on the concept of the present disclosure still belong to the protection scope of the present invention.
[0140] Unless otherwise defined, the definitions of all technical and scientific terms used herein are the same as those familiar to those skilled in the art. Any methods and materials similar or equivalent to those described herein can be applied to the methods of the present disclosure, and preferred methods and materials are described in specific embodiments.
[0141] As used herein, the terms "a" and "a kind" refer to the grammatical indefinite article interpretation, meaning "one," "a kind," or "plural," "several kinds" (i.e., "at least one," "at least one kind"). For example, "an element" means one or more elements.
[0142] "CDS" is an abbreviation for coding sequence, which means any nucleotide sequence for encoding a polypeptide product of a gene. Conversely, the term "non-coding sequence" means any nucleotide sequence that does not encode a polypeptide product of a gene.
[0143] The term "fragment" should be understood to mean a nucleotide sequence that is shorter in length than the reference nucleic acid and contains the same nucleotide sequence as the reference nucleic acid in the common portion. If appropriate, such nucleic acid fragments according to the present disclosure may be included in a larger polynucleotide, and the fragments are components of the larger polynucleotide. Such fragments include or alternatively consist of oligonucleotides with lengths within at least 6, 8, 9, 10, 12, 15, 18, 20, 21, 22, 23, 24, 25, 30, 39, 40, 42, 45, 48, 50, 51, 54, 57, 60, 63, 66, 70, 75, 78, 80, 90, 100, 105, 120, 135, 150, 200, 300, 500, 720, 900, 1000 or 1500 consecutive nucleotides of the nucleic acid of the present disclosure.
[0144] In this specification, unless the context requires otherwise, the words "comprise" and "contain" are to be understood as including the step or element or collection of steps and elements, but not excluding any other step or element or collection of steps and elements, i.e., open ended.
[0145] By "corresponding" it is meant that (a) a polynucleotide has a nucleotide sequence that is substantially identical or complementary to all or a portion of a reference nucleotide sequence, or that a polynucleotide encodes an amino acid sequence that is entirely identical to an amino acid sequence in a peptide or protein, or (b) a peptide or polypeptide has an amino acid sequence that is substantially identical to an amino acid sequence in a reference peptide or protein.
[0146] The term "downstream" refers to a nucleotide sequence located at the 3' end of a reference nucleotide sequence. In particular, a downstream nucleotide sequence usually refers to a sequence following the transcription start point. For example, the translation start codon of a gene is located downstream of the transcription start site.
[0147] The term "upstream" refers to a nucleotide sequence located at the 5' end of a reference nucleotide sequence. In particular, upstream nucleotides usually relate to sequences located 5' of a coding sequence or transcription start site. For example, most promoters are located upstream of the transcription start site.
[0148] By "promoter" is meant a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. Generally, the coding sequence is located at the 3' end of the promoter sequence. A promoter may be entirely derived from a native gene, or may be composed of different elements derived from different promoters found in nature, or may even include synthetic DNA segments. As will be appreciated by those skilled in the art, different promoters can direct genes to be expressed in different tissues or cell types, or at different stages of development, or in response to different environmental or physiological conditions. A promoter that causes a gene to be expressed in most cell types most of the time is usually called a "constitutive promoter". A promoter that causes a gene to be expressed in a particular cell type is usually called a "cell-specific promoter" or "tissue-specific promoter". A promoter that causes a gene to be expressed at a particular developmental or cell differentiation stage is usually called a "developmental specific promoter" or "cell differentiation specific promoter". A promoter that causes a gene to be expressed in a manner that is induced after exposing or treating cells with a drug, biomolecule, chemical, ligand, light, or the like that induces the promoter is usually called an "inducible promoter" or "regulatable promoter". It should be further understood that in most cases, the exact limits of a regulatory sequence are not completely defined, so that DNA segments of different lengths may have the same promoter activity.
[0149] The terms "5'UTR" or "5'non-coding sequence" or "5'untranslated region (UTR)" refer to a DNA sequence located upstream (5') to a coding sequence.
[0150] The terms "restriction endonucleases" and "restriction enzymes" refer to enzymes that bind to and cut specific nucleotide sequences within double-stranded DNA.
[0151] The term "vector" refers to a nucleic acid molecule capable of transferring a nucleic acid molecule to which it is ligated. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which other DNA segments can be ligated. Another type of vector is a viral vector, in which other DNA segments can be ligated into the viral genome. Some vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of the host cell after introduction into the host cell, and thus are replicated along with the host genome. Moreover, some vectors can direct the expression of genes to which they are operatively linked.
[0152] Some vectors are referred to in this disclosure as "recombinant expression vectors" (or simply "expression vectors"), which refers to vectors, plasmids, or vehicles designed to allow expression of an inserted nucleic acid sequence following transformation into a host. In short, expression vectors used in recombinant DNA techniques are always in the form of a plasmid. "Plasmid" and "vector" are used interchangeably herein, as plasmids are the most commonly used form of vector. However, the present disclosure is intended to include other forms of such expression vectors, such as viral vectors (e.g., replication-defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent roles.
[0153] The term "plasmid" refers to an extrachromosomal element, which always carries genes that are not part of the central metabolism of the cell, and which always takes the form of a circular double-stranded DNA molecule. Such elements may be autonomously replicating sequences, genome-integrating sequences, phages, or nucleotide sequences of any origin, linear, circular, or supercoiled, single-stranded or double-stranded DNA or RNA, among others, many of which have already been linked or recombined into unique structures that allow the introduction of promoter fragments and DNA sequences for selected gene products, as well as appropriate 3'-end untranslated sequences, into cells.
[0154] A "targeting vector" or "targeting vector" is a DNA construct that contains sequences "homologous" to endogenous chromosomal nucleic acid sequences that flank a desired genetic modification. The flanking homologous sequences (called "homology arms") direct the targeting vector to locate at a specific chromosomal location in the genome due to the homology that exists between the homology arms and the corresponding endogenous sequences, and introduce the desired genetic modification by a process called "homologous recombination." "Targeting vector" and "targeting" are sometimes used interchangeably. A targeting vector is employed to introduce an insert nucleic acid into a target locus of a rat, eukaryote, non-rat eukaryote, mammal, non-human mammal, human, rodent, non-rat rodent, mouse, or hamster nucleic acid. The targeting vector contains the insert nucleic acid and further contains a 5' homology arm and a 3' homology arm to which the insert nucleic acid is flanked. The homology arms flanking the insert nucleic acid correspond to regions within a target locus of a rat, eukaryotic, non-rat eukaryotic, mammal, non-human mammal, human, rodent, non-rat rodent, mouse, or hamster nucleic acid. For ease of explanation, the corresponding homologous genomic regions within the target genomic locus are referred to herein as "target sites." For example, a targeting vector can include a first insert nucleic acid flanking the first and second homology arms that are complementary to a first and second target site. The targeting vector thus serves to integrate the insert nucleic acid into a target locus of a rat, eukaryotic, non-rat eukaryotic, mammal, non-human mammal, human, rodent, non-rat rodent, mouse, or hamster nucleic acid via a homologous recombination event that occurs between the homology arms and the complementary target site within the genome of the cell.
[0155] In one embodiment, the target locus of the rat, eukaryotic, non-rat eukaryotic, mammalian, non-human mammalian, human, rodent, non-rat rodent, mouse or hamster nucleic acid comprises a first nucleic acid sequence that is complementary to the 5' homology arm and a second nucleic acid sequence that is complementary to the 3' homology arm.
[0156] Vectors can be introduced into the desired host cells by methods known in the art, such as, for example, transfection, electroporation, microinjection, transduction, cell fusion, DEAE-dextran, calcium phosphate precipitation, lipofection (lysosomal fusion), gene guns, or the use of DNA vector transporters (see, e.g., Wu et al., 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263:14621-14624; and Hartmut et al., Canadian Patent Application 2,012,311, filed March 15, 1990).
[0157] The term "transfection" refers to the uptake of exogenous or heterologous RNA or DNA by a cell. A cell has been "transfected" by such RNA or DNA when the transfecting RNA or DNA affects a phenotypic change. A cell has been "transformed" by exogenous or heterologous RNA or DNA when the transfecting RNA or DNA affects a phenotypic change. The transforming RNA or DNA may be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
[0158] The term "homology" or "homologous" means that two sequences, e.g., nucleotide or amino acid sequences, are identical in at least about 75% of the nucleotides or amino acids, at least about 80% of the nucleotides or amino acids, at least about 90-95% of the nucleotides or amino acids, e.g., more than 97% of the nucleotides or amino acids, by optimal control and comparison. As will be understood by those skilled in the art, for optimal gene targeting, the targeting construct should contain arms that are homologous to the endogenous DNA sequence (i.e., "homology arms"). Thus, homologous recombination can occur between the targeting construct and the targeted endogenous sequence.
[0159] As used herein, a homology arm and a target site (i.e., a homologous genomic region) are complementary to each other when the two regions have a sufficient level of sequence identity with each other, thereby serving as a substrate for a homologous recombination reaction. "Homology" means that a DNA sequence is identical to or shares sequence identity with a corresponding or "complementary" sequence. The sequence identity between a given target site and a corresponding homology arm found on a targeting vector may be any degree of sequence identity that allows homologous recombination to occur. For example, the amount of sequence identity shared by a homology arm (or a fragment thereof) of a targeting vector and a target site (or a fragment thereof) may be at least 51%, 53%, 57%, 60%, 65%, 70%, 75%, 80%, 83%, 85%, 87%, 89%, 91%, 93%, 95%, 97%, 98%, 99% or 100% sequence identity, such that the sequences undergo homologous recombination. It should be noted that the complementary homology region between the homology arm and the complementary target site can have any length sufficient to promote homologous recombination at the cleaved recognition site. Thus, the homology arm has sufficient homology to perform homologous recombination with the corresponding target site in the genome of the cell. For ease of explanation, the homology arm is referred to herein as the 5' homology arm and the 3' homology arm. The term refers to the relative position of the homology arm and the inserted nucleic acid in the targeting vector.
[0160] In some embodiments, the homology arms of the targeting vector can be of any length sufficient to facilitate a homologous recombination event with a corresponding target site, including, for example, at least 5-10 kb, 5-15 kb, 10-20 kb, 20-30 kb, 30-40 kb, 40-50 kb, 50-60 kb, 60-70 kb, 70-80 kb, 80-90 kb, 90-100 kb, 100-110 kb, 110-120 kb, 120-130 kb, 130-140 kb, 140-150 kb, 150-160 kb, 160-170 kb, 170-180 kb, 180-190 kb, 190-200 kb or longer in length. As described in more detail below, the targeting vector can employ targeting arms of greater length. In certain embodiments, the sum of the 5' homology arm and the 3' homology arm is at least 10 kb, or the sum of the 5' homology arm and the 3' homology arm is at least about 16 kb to about 100 kb, or about 30 kb to about 100 kb, and in other embodiments, the sum of the 5' homology arm and the 3' homology arm of the ACE2 is about 10 kb to about 150 kb, about 10 kb to about 100 kb, about 10 kb to about 75 kb, about 20 kb to about 150 kb, about 20 kb to about 100 kb, about 20kb to about 75kb, about 30kb to about 150kb, about 30kb to about 100kb, about 30kb to about 75kb, about 40kb to about 150kb, about 40kb to about 100kb, about 40kb to about 75kb, about 50kb to about 150kb, about 50kb to about 100kb, or about 50kb to about 75kb, about 10kb to about 30kb, about 20kb to about 40kb, about 40kb to about 60kb, about 60kb to about 80kb, about 80kb to about 100kb, about 100kb to about 120kb, or about 120kb to about 150kb.
[0161] Some examples herein relate to a humanized gene-edited mammal, wherein the genome of the humanized gene-edited mammal comprises a polyribonucleic acid encoding a full-length human ACE2 protein. For example, the polyribonucleic acid is operably linked to a promoter polyribonucleic acid. In some embodiments, the humanized gene-edited mammal does not express all or a portion of the polyribonucleic acid encoding the endogenous ACE2 protein of the humanized gene-edited mammal, and the polyribonucleic acid encoding the human ACE2 protein comprises a modification of the human ACE2 protein.
[0162] In some embodiments, the cell is a pluripotent cell, a non-pluripotent cell, a mammalian cell, a human cell, a non-human mammalian cell, a rodent cell, a mouse cell, a hamster cell, a non-human pluripotent cell, a human pluripotent cell, a rodent pluripotent cell, or a fibroblast cell or a lung cell.
[0163] In some of the above methods, the cells are primary cells or immortalized cells. In some of the above methods, the rodent pluripotent cells are mouse or rat embryonic stem (ES) cells.
[0164] In some of the above methods, the animal or human cell is a primary cell or an immortalized cell. In some of the above methods, the animal or human cell is a pluripotent cell. In some of the above methods, the animal pluripotent cell is a mouse embryonic stem (ES) cell. In some of the above methods, the human pluripotent cell is a human embryonic stem (ES) cell, a human adult stem cell, a developmentally restricted human progenitor cell, or a human induced pluripotent stem (iPS) cell.
[0165] In some embodiments, some examples herein provide humanized gene-edited cells, and in particular isolated human and non-human totipotent or pluripotent stem cells, in particular mouse embryonic stem cells, which maintain pluripotency after one or more in vitro sequential genetic modifications and are capable of transmitting said targeted gene modifications to progeny via the germline.
[0166] The term "embryonic stem cell" or "ES cell" as used herein includes totipotent or pluripotent cells derived from an embryo that can promote the development of any tissue of the embryo after introduction into the embryo. The term "pluripotent cell" as used herein includes undifferentiated cells that have the ability to develop into two or more types of differentiated cells. The term "non-pluripotent cell" includes cells that are not pluripotent cells.
[0167] In some of the above methods, the targeted gene editing simultaneously comprises a deletion of an endogenous nucleic acid sequence at the target genomic locus or an insertion of the nucleic acid at the target genomic locus.
[0168] In some embodiments, the genetic modification or gene editing comprises two or more modifications performed independently on a cell (e.g., a eukaryotic cell, a non-rat eukaryotic cell, a mammalian cell, a human cell, a non-human mammalian cell, a pluripotent cell, a non-pluripotent cell, a non-human pluripotent cell, a human pluripotent cell, a human ES cell, a human adult stem cell, a developmentally restricted human progenitor cell, a human iPS cell, a human cell, a rodent cell, a non-rat rodent cell, a rat cell, a mouse cell, a hamster cell, a fibroblast cell, or a Chinese hamster ovary (CHO) cell). The first modification can be achieved by electroporation or any other method known in the art. A second modification is then performed on the same cell genome using an appropriate second nucleic acid construct. The third modification can be achieved by a second electroporation or any other method known in the art. In various embodiments, after a first genetic modification and a second genetic modification of the same cell, successive modifications can be achieved (sequentially) a third genetic modification, a fourth genetic modification, a fifth genetic modification, a sixth genetic modification, etc. (one genetic modification follows another) using, for example, sequential electroporation or any other suitable method known in the art.
[0169] In some embodiments, the present disclosure provides gene editing by a homologous recombination method of a targeting vector to insert an exogenous nucleic acid into an endogenous genome.
[0170] In some embodiments, the insert nucleic acid comprises a eukaryotic, non-rat eukaryotic, mammalian, human or non-human mammalian nucleic acid sequence for inserting or substituting a homologous or orthologous human nucleic acid sequence.
[0171] In some embodiments, the inserted polynucleotide of interest can be derived from any organism, including, for example, a rodent, a non-rat rodent, a rat, a mouse, a hamster, a mammal, a non-human mammal, a eukaryote, a non-rat eukaryote, a human, an agricultural animal, or a livestock animal.
[0172] In certain embodiments, the insert nucleic acid can comprise a nucleic acid from a rat, which can comprise a fragment of genomic DNA, a cDNA, a regulatory region, or any portion or combination thereof. In other embodiments, the nucleic acid can comprise a nucleic acid from a eukaryote, a non-rat eukaryote, a mammal, a human, a non-human mammal, a rodent, a non-rat rodent, a human, a rat, a mouse, a hamster, a rabbit, a pig, a cow, a deer, a sheep, a goat, a chicken, a cat, a dog, a ferret, a primate (e.g., marmoset, rhesus monkey), a domesticated mammal, or an agricultural mammal, or any other target organism. As outlined in more detail herein, the insertion of a nucleic acid employed in various methods and compositions can result in "humanization" of the target locus of interest.
[0173] In some embodiments, the genetic modification is the addition of a nucleic acid sequence. In some embodiments, the insert nucleic acid comprises a genetic modification in a coding sequence. In some embodiments, the genetic modification comprises a deletion mutation of a coding sequence. In some embodiments, the genetic modification comprises a fusion of two endogenous coding sequences. In some embodiments, the insert nucleic acid comprises inserting or replacing a homologous or orthologous human nucleic acid sequence for a eukaryotic, non-rat eukaryotic, mammalian, human or non-human mammalian nucleic acid sequence. In some embodiments, the insert nucleic acid comprises inserting or replacing a homologous or orthologous human nucleic acid sequence in an endogenous mouse gene coding region that includes a corresponding mouse DNA sequence. In some embodiments, the insert nucleic acid comprises inserting or replacing a homologous or orthologous human nucleic acid sequence in an endogenous mouse gene coding region that includes a corresponding mouse DNA sequence. In some embodiments, a targeting vector is used to insert a hACE2 sequence into the EXON1 CDS start ATG site adjacent to mACE2 for the mouse ACE2 site.
[0174] In some embodiments, the nucleic acid sequence of the targeting vector can include a polynucleotide that, when integrated into the genome, generates a genetic modification of a region of the ACE2 locus of a mammal, human, or non-human mammal, where the genetic modification at the ACE2 locus causes a decrease in ACE2 activity, an increase in ACE2 activity, or a modulation of ACE2 activity, in some embodiments, a complete replacement of the ACE2 gene is generated.
[0175] In some embodiments, the insert nucleic acid can include a regulatory element, such as a promoter, enhancer, or transcription element.
[0176] In some embodiments, a given inserted polynucleotide and / or corresponding replacement region of a mammalian, human cell or non-human mammalian locus may be a coding region, an intron, an exon, an untranslated region, a regulatory region, a promoter or enhancer, or any combination thereof.
[0177] Provided herein are methods for generating gene-edited cells by introducing sequences as outlined above, which allow targeted integration of one or more polynucleotides of interest into a target locus. "Introducing" refers to presenting a sequence (polypeptide or polynucleotide) to a cell such that the sequence enters the interior of the cell.
[0178] Any cell from any organism can be used in the methods provided herein. In certain embodiments, the cell is from a eukaryote, a non-rat eukaryote, a mammal, a non-human mammal, a human, a rodent, a non-rat rodent, a rat, a mouse, or a hamster. In certain embodiments, the cell is a eukaryote, a non-rat eukaryote, a pluripotent cell, a non-pluripotent cell, a non-human pluripotent cell, a non-human mammalian cell, a human pluripotent cell, a human ES cell, a human adult stem cell, a developmentally restricted human progenitor cell, a human induced pluripotent cell (iPS) cell, a mammalian cell, a human cell, a fibroblast, a rodent cell, a non-rat rodent cell, a rat cell, a mouse cell, a mouse ES cell, a hamster cell, or a CHO cell.
[0179] In some embodiments, the cells employed in the methods have the DNA construct stably integrated into their locus. "Stably integrated" or "stably introduced" refers to introducing a polynucleotide into a cell such that the nucleotide sequence can be integrated into the genome of the cell and inherited by its progeny.
[0180] In some embodiments, one or more polynucleotides are introduced into a cell via electroporation, intracytoplasmic injection, viral infection, adenovirus, lentivirus, retrovirus, transfection, lipid-mediated transfection, or Nucleofection™ mediation.
[0181] In some embodiments, the expression construct is introduced along with the introduced nucleic acid.
[0182] In some embodiments, the introduction of the one or more polynucleotides into the cell can be performed multiple times over a period of time. In some embodiments, the introduction of the one or more polynucleotides into the cell can be performed at least 2 times over a period of time, at least 3 times over a period of time, at least 4 times over a period of time, at least 5 times over a period of time, at least 6 times over a period of time, at least 7 times over a period of time, at least 8 times over a period of time, at least 9 times over a period of time, at least 10 times over a period of time, at least 11 times over a period of time, at least 12 times over a period of time, at least 13 times over a period of time, at least 14 times over a period of time, at least 15 times over a period of time, at least 16 times over a period of time, at least 17 times over a period of time, at least 18 times over a period of time, at least 19 times over a period of time, or at least 20 times over a period of time.
[0183] In some embodiments, the targeting vector (containing the introduced nucleic acid) and the expression vector (containing the sgRNA) are introduced into the cell simultaneously.
[0184] In some embodiments, there is further provided a method for producing a humanized non-human animal comprising: (a) forming a donor cell by modifying the genome of a pluripotent cell with a targeting vector comprising an insert nucleic acid, said insert nucleic acid comprising a human nucleic acid sequence; (b) introducing said donor cell into a host embryo; and (c) gestating said host embryo in a surrogate mother, wherein said surrogate mother produces offspring comprising said human nucleic acid sequence. In some embodiments, said donor cell is introduced into a host embryo at the blastocyst stage or pre-morula stage (i.e., 4-cell stage or 8-cell stage). In further embodiments, said genetic modification can be transmitted through the germline.
[0185] In some particular embodiments, a method for producing a humanized mouse is provided, comprising: (a) introducing a targeting vector containing an ACE2 gene fragment and an expression vector linked to an sgRNA into a mouse embryonic cell to form a donor cell for gene editing; (b) introducing the donor cell into a mouse embryo; and (c) carrying the mouse embryo in a surrogate mother, wherein the surrogate mother produces offspring comprising the human ACE2 sequence.
[0186] In this specification, the term "tetraploid complementation technology" may be equivalent to "tetraploid embryo compensation technology" or "tetraploid complementation method" or "tetraploid embryo complementation method", which means chimerizing a certain number of embryonic stem (ES) cells and a tetraploid embryo, and during the development of the chimera, the ES cells and the tetraploid embryo are not randomly distributed, i.e., the tetraploid embryo part is only involved in the formation of extraembryonic tissues such as yolk sac endoderm and placental trophoblast cells (e.g. chorionic ectoderm, trophoblast cells, etc.), and the ES cells are widely involved in the generation of embryoid bodies, allantois, amnion, yolk sac mesoderm and chorionic mesoderm parts, but are not involved in the generation of yolk sac endoderm and placental trophoblast cell lineages, i.e., the developmental abilities of both are complementary, and such a phenomenon is called tetraploid complementation technology.
[0187] In some cases, the term "embryo" refers to something derived from an animal subject at any time before birth, or from tissues and cells within an animal subject at any time before birth.
[0188] In some cases, "embryo" is used to refer to a fertilized oocyte that is implanted in the uterus before becoming a fetus at 8 weeks after fertilization. According to this definition, a fertilized oocyte is usually called a pre-embryo before implantation. However, throughout this patent application, we use a broader term to define an embryo, which includes the pre-embryo stage. It therefore includes all stages of development from fertilization of the oocyte to morula, hatching of the blastocyst, and implantation.
[0189] The embryo is roughly spherical and consists of one or more cells (blastomeres) surrounded by a gelatinous shell and a cell-free matrix called the zona pellucida. The zona pellucida performs a variety of functions until the embryo hatches, and is an excellent marker for embryo evaluation. The zona is spherical, translucent, and clearly distinguishable from cellular debris.
[0190] The mammalian preimplantation embryo is approximately 90-120 microns in diameter and has a clearly visible zona pellucida on its outer surface, composed of glycoproteins. One side of the fertilized egg shows a polar body formed during one or two meiotic divisions.
[0191] After the egg undergoes the first mitosis between 23-43.5 hours after fertilization, an embryo with two blastomeres is formed. The cells of the 2-cell stage embryo are nearly oval and nearly equal in size, and after an electric shock, the two blastomeres can fuse into a tetraploid cell, which then develops into a tetraploid embryo. The fertilized egg divides in two to form two blastomeres, i.e., the 2-cell stage, and then the two blastomeres divide in two to form four, i.e., the 4-cell stage. The blastomeres divide in two to form eight, i.e., the 8-cell stage, and when they divide five times into 32 cells, i.e., the morula is formed. At the 4-cell stage, the four blastomeres are seen to be arranged in a cross-like fashion. At the 8-cell stage, the blastomeres are arranged in two layers, one above the other, and begin to compact as tight connections form. From the 16-cell stage, the embryo is called a morula, and differentiation of the inner cell mass and trophoblast appears. 72 hours after fertilization, the embryo develops to the 32-cell stage, gaps appear between the blastomeres, and after enlarging, a complete blastocoel is formed, with a mass of cells on one side of the cavity, the inner cell mass. The layer of flattened cells surrounding the blastocoel is called the trophoblast. At this point, the blastula is also called a blastocyst. The late blastocyst expands and pushes out of the zona pellucida, becoming a hatched blastocyst.
[0192] The term embryo is used to refer to fertilized oocyte, zygote, 2-cell, 4-cell, 8-cell, 16-cell, morula, blastocyst, expanded blastocyst and hatched blastocyst, and all stages in between (e.g. 3-cell or 5-cell).
[0193] As used herein, "chimeric blastula" or "chimeric embryo" refers to a chimeric blastula or embryo containing embryonic stem cells. In addition to being produced by the injection method, the chimeric blastula or embryo can also be produced, for example, by the so-called "aggregation method," in which embryo+embryo or embryo+cell are brought into close contact with each other in a petri dish with a lid to produce a chimeric blastula. Furthermore, the relationship between the recipient blastula or embryo and the cells to be transplanted in the present disclosure can be an allogeneic or heterogeneous relationship.
[0194] As used herein, the term "administration" or "implantation" refers to a method or route of producing a desired effect by at least partially positioning cells at a desired site, where the cells are intended to be placed in a subject.
[0195] Example 1 Construction of ACE2 gene sgRNA1 and pX330-sgRNA plasmid Synthesize the sgRNA1 sequence that will identify the target site. sgRNA1 sequence (SEQ ID NO:1): 5'-tactgctcagtccctcaccgagg-3' The upstream and downstream annealing primers of the sgRNA are synthesized by introducing a BbsI restriction site into the sgRNA site for subsequent annealing experiments. The sequences of the upstream and downstream single-stranded primers for synthesizing sgRNA1 are as follows: Upstream: 5'-caccgcttggcattttcctcggtga-3'(SEQ ID NO:4) Downstream: 5'-aaactcaccgaggaaaatgccaagc-3'(SEQ ID NO:5) Origin of pX330 plasmid: The pX330 vector map is shown in Figure 1. The plasmid backbone is derived from the Miaoling plasmid platform and is part number P0123. The above sgRNA annealing primers are annealed and then ligated into the pX330 plasmid (the plasmid is first linearized with BbsI) to obtain the expression vector pX330-sgRNA1. A specific ligation reaction system is shown in Table 1. [Table 1] The reaction conditions are as follows: Ligate at 16°C for 30 min or more, transform into 30 μL of TOP10 competent cells, then take 200 μL and spread it on an Amp-resistant plate, and after culturing at 37°C for at least 12 h, select two clones and inoculate them into LB medium (5 mL) containing Amp-resistant, and culture at 37°C with shaking at 250 rpm for at least 12 h. The randomly selected clones were sent to a sequencing company for sequencing verification. The sequencing results are shown in Figure 2. The expression vector pX330-sgRNA1 with correct ligation was selected for subsequent experiments.
[0196] Example 2 Construction of ACE2 gene sgRNA2 and pX330-sgRNA2 plasmid Synthesize the sgRNA2 sequence that will identify the target site. sgRNA2-Sequence (SEQ ID NO:2): 5'-cttggcattttcctcggtgaggg-3' The upstream and downstream annealing primers of the sgRNA are synthesized by introducing a BbsI restriction site into the sgRNA site for subsequent annealing experiments. The sequences of the upstream and downstream single-stranded primers for synthesizing sgRNA2 are as follows: Upstream: 5'-caccgtactgctcagtccctcaccg-3'(SEQ ID NO:6) Downstream: 5'-aaaccggtgagggactgagcagtac-3'(SEQ ID NO:7) Origin of pX330 plasmid: The pX330 vector map is shown in Figure 1. The plasmid backbone is derived from the Miaoling plasmid platform and is part number P0123. The above sgRNA annealing primers are annealed and then ligated into the pX330 plasmid (the plasmid is first linearized with BbsI) to obtain the expression vector pX330-sgRNA2. A specific ligation reaction system is shown in Table 2. [Table 2] The reaction conditions are as follows: Ligate at 16°C for 30 min or more, transform into 30 μL of TOP10 competent cells, then take 200 μL and spread it on an Amp-resistant plate, and after culturing at 37°C for at least 12 h, select two clones and inoculate them into LB medium (5 mL) containing Amp-resistant, and culture at 37°C with shaking at 250 rpm for at least 12 h. The randomly selected clones were sent to a sequencing company for sequencing verification. The sequencing results are shown in Figure 3. The expression vector pX330-sgRNA2 with correct ligation was selected for subsequent experiments.
[0197] Example 3 Identification of the cleavage efficiency of pX330-sgRNA 2 μg of each of the pX330-sgRNA plasmids prepared in Example 1 and Example 2 was transfected into mouse embryonic stem cells using Lipofectamine 3000 (Invitrogen, Product No. L3000001) method. For specific transfection procedures, refer to the Lipofectamine 3000 reagent operating instructions. Mouse embryonic stem cells were collected two days after transfection, and genomes were extracted using a cell genome extraction kit (Tiangen, DP304-02). Next, upstream and downstream primers for PCR were designed on both sides of the genome cleavage site, and the upstream primer (5arm-sgF:ggttttgatttggccataaaatgttagc (SEQ ID NO: 10)) and downstream primer (3arm-sgR:attcccaggtccagtttcacctaag (SEQ ID NO: 11)) were used to perform PCR reaction on the extracted genome (using Novozan's Phanta Max Super-Fidelity DNA Polymerase). Next, we used T7 endonuclease I (T7EI) (Biolabs, M0302L) to verify the cleavage efficiency of pX330-sgRNA. In principle, T7 endonuclease I can identify and cleave incompletely paired DNA. The specific operation steps of the T7EI experiment are as follows: The genome was extracted from the above cells transfected with pX330-sgRNA1 and pX330-sgRNA2, respectively, and the PCR product obtained by 5arm-sgF+3arm-sgR amplification was collected (Tiangen, DP214-02). 1 μg was taken for the annealing reaction, and the reaction system was as follows: [Table 3] Next, 1 μL of T7 endonuclease I is added to the annealed product and reacted at 37 ° C for 30 min, after which verification is performed by gel electrophoresis. The results of gel electrophoresis are shown in Figure 4. sgRNA1 and sgRNA2 in Examples 1 and 2 have high brightness of the cleavage bands (sgRNA1 can be cleaved into two bands of about 376 bp and 581 bp, and sgRNA2 can be cleaved into two bands of about 371 bp and 586 bp), and have high cleavage efficiency. Since the cleavage efficiency is mainly shown in the figure, the cleavage efficiency of another sgRNA (denoted as sgRNA3) is also shown in Figure 4 to show the effect of the solutions in Examples 1 and 2. Listed sgRNRA3 sequence (SEQ ID NO:3): 5'-caagtgaactttgataagacagg-3' The sequences of the upstream and downstream single-stranded primers for synthesizing sgRNA3 are as follows: Upstream: 5'-caccgcaagtgaactttgataagac-3'(SEQ ID NO:8) Downstream: 5'-aaacgtcttatcaaagttcacttgc-3'(SEQ ID NO:9) The other steps are the same as in Example 1. The randomly selected clones were sent to a sequencing company for sequencing verification, and the sequencing results were as shown in Figure 5. The expression vector pX330-sgRNA3 with correct ligation was selected for further experiments. The construction of other sgRNAs and pX330-sgRNA plasmids is not the focus of this disclosure, so description and enumeration will be omitted.
[0198] Example 4. Targeting vector design The human ACE2 gene (Gene ID: ID: 59272) CDS protein coding sequence (a transcript based on NCBI accession number NM_001371415.1 → NP_001358344.1, the CDS sequence (hACE2-CDS) is as shown in SEQ ID NO: 12, and the protein sequence (hACE2-protein) is as shown in SEQ ID NO: 13) is inserted into the promoter and 5'UTR region sequence of mouse Ace2, and then the mouse Ace2 promoter is used to drive the gene expression of human ACE2. At the same time, the termination signal of the SV40 polyA sequence signal (the SV40-polyA sequence is as shown in SEQ ID NO: 14) is added after the inserted CDS sequence of human ACE2 to enhance the transcription termination of human ACE2 mRNA. Based on the sequence design, the inventors further designed a targeting scheme as shown in Figure 6 and a vector including a 5' homology arm (5arm), a human ACE2 gene fragment and a 3' homology arm (3arm), where the 5' homology arm is nucleotides 125683-126652 in NCBI Accession No. AC091606.8 (the 5' homology arm sequence is as shown in SEQ ID NO:15) and the 3' homology arm is nucleotides 126796-127766 in NCBI Accession No. AC091606.8 (the 3' homology arm sequence is as shown in SEQ ID NO:16). At the same time, PGK-puromycin heterologous gene package is also inserted into the vector for screening purposes, and a pair of unidirectional frt sites (SEQ ID NO:18) are designed at both ends of the puromycin resistance gene (PGK-puro, SEQ ID NO:17) expression cassette, so that the FLP recombinase can be used to remove them and solve the safety problem caused by gene recombination. The constructed vector is fully sequence verified. Before targeting, the vector is linearized by AgeI (the schematic diagram of the targeting vector and the schematic diagram of the targeting scheme are shown in Figure 6). The process of constructing the vector is as follows. An upstream primer (5arm-pcrF: tcgcacacattccacatccaccggtccctatggagtggagaagagtctta (SEQ ID NO:19)) and a matching downstream primer (5arm-pcrR: gaaggagccaggaagagcttgacatctttccccgtgcgccaagatcc (SEQ ID NO:20)) are designed to amplify the bridge fragment of the 5' homology arm. An upstream primer (hACE2-F: ggatcttggcgcacggggaaagatgtcaagctcttcctggctccttc (SEQ ID NO: 21)) and a matching downstream primer (hACE2-R: cattataagctgcaataaacaagttctaaaaggaggtctgaacatcatc (SEQ ID NO: 22)) are designed to amplify the bridge fragment of human ACE2 CDS. An upstream primer (SV40-F: gatgatgttcagacctccttttagaacttgtttattgcagcttataatg (SEQ ID NO: 23)) and a matching downstream primer (SV40-R: AGAGAATAGGAACTTCGCACGCGTtaagatacattgatgagtttggac (SEQ ID NO: 24)) are designed to amplify the bridging fragment of SV40 polyA. An upstream primer (3arm-pcrF: tacgaagttatGtcgacgcGGCGCGCCgaattataatactaacattactg (SEQ ID NO: 25)) and a matching downstream primer (3arm-pcrR: tatgaccatgattacgccaagcttaagaccaaactattagagcagttaaaagc (SEQ ID NO: 26)) for amplifying the 3' homology arm fragment are designed. The amplification template for the 5' homology arm and 3' homology arm is C57BL6 / J mouse genome, and the amplification template for human ACE2 is human lung cell cDNA. The PCR reaction system (using Novozan's Phanta Max Super-Fidelity DNA Polymerase) and conditions are as shown in Table 4. [Table 4] For example, the product fragments obtained by PCR amplification, 5' homology arm, human ACE2 CDS, and SV40 polyA, are PCR-generated into a continuous fragment 5arm-hACE-SV40 using bridge PCR (overlap PCR) and Touch-down PCR. Also, the 3' homology arm obtained by PCR amplification is recovered and then directly used to construct a homologous recombination targeting vector, and the construction process is as follows: The 1.5arm-hACE-SV40 fragment is subjected to AgeI+MluI double digestion, and the 3' homology arm fragment is subjected to AscI+HindIII double digestion, followed by ligation using the digestion-ligation method to obtain the targeting vector. 2. The positive targeting vector obtained after digestion identification was sent for sequencing identification, and the sequence was verified to be accurate by the sequencing company (shown in Figure 7), thereby successfully obtaining the humanized ACE2 targeting vector. The entire targeting vector sequence is shown in SEQ ID NO:27.
[0199] Example 5 The product fragments obtained by PCR amplification, 5' homology arm, human ACE2 CDS, and SV40 polyA, are PCRed into a continuous fragment 5arm-hACE-SV40 using bridge PCR (overlap PCR) method. The PCR reaction conditions are as shown in Table 5, and other conditions are the same as those in Example 4. [Table 5] As a result, as shown in FIG. 8, it was not possible to amplify a fragment in which the three fragments were linked.
[0200] Example 6. Obtaining humanized ACE2 mouse embryonic stem cells In one embodiment, humanized ACE2 mouse embryonic stem cells can be obtained by the following method. (1) C57BL6 / J mouse embryonic stem cells (the embryonic stem cells are derived from an established embryonic stem cell line) are resuscitated from a liquid nitrogen cryopreserved cell bank, specifically mouse embryonic stem cells within passage number p10 are used, and grown in culture in 6 cm Petri dishes for 3 days. (2) Nucleofector TM Using a combination of IIs / 2b electroporator and a Mouse ES Cell Nucleofector® Kit (Lonza, VPH-1001) mouse embryonic stem cell electroporation kit, approximately 2 × 10 cells were electroporated using the A023 program. 6 Embryonic stem cells are electroporated, and the electroporation process is carried out in 100 μL of electroporation buffer containing 3 μg of linearized targeting vector (targeting vector of Example 4) and 1 μg of pX330-sgRNA1. The transfected cells are seeded into three wells of a 6-well plate, cultured, and allowed to recover for 36 hours. After recovery, 1 μg / mL of puromycin (Merck) is added to the cell culture medium. After 3-4 days of screening, puromycin-resistant mouse embryonic stem cell clones were selected by aspirating monoclones using a glass needle and cultured in a 96-well plate. The next day, the monoclones were trypsinized and divided into two parts, one of which was lysed alone in 10 μL of NP40 lysis buffer at 56°C for 60 minutes, and then at 95°C for 10 minutes. Here, the specific steps of culturing the other mouse embryonic stem cells are as follows: Prepare the feeding layer feeder cells one day in advance, spread them on different well plates as necessary, and culture them overnight to form a monolayer. Here, the feeding layer feeder cells are mouse embryonic fibroblasts prepared by treatment with the mitomycin C (MMC) method. Culture them using mES medium containing LIF and 2i (chir 99021 and pD0325901 inhibitor), replace with fresh medium every day, and increase the medium appropriately according to the growth status of the cells. Generally, one generation is subcultured every 3 days, digested with 0.25% trypsin at the time of subculture, and seeded at a density of about 300,000 in a 6 cm dish and about 100,000 per well in a 6-well plate. The composition of mES+LIF+2i medium is as follows: Knockout DMEM (1x, Gibco) + 15% FBS (FRONT BIOMEDICAL, 0.22 μm Millipore filter) + GlutaMAX (100x, Gibco) + NEAA (100x, Gibco) + P / S (P: 50 units, S: 50 mg / ml, Hyclone) + β-mercaptoethanol (Gibco, working concentration 0.1 mM) + LIF (1000 units / ml, Millipore) + CHIR99021 (GSK3β inhibitor, working concentration 3 μM) + PD0325901 (MEK inhibitor, working concentration 1 μM). The composition of the NP40 dissolution solution is as follows: 10 mL TE (20 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA) + 0.5% NP40 + 10 μL protease K (10 mg / mL). In the above method, pX330-sgRNA1 is replaced with pX330-sgRNA2 or pX330-sgRNA3, and other steps are the same as pX330-sgRNA1. The targeting effects of the combinations of pX330-sgRNA1, pX330-sgRNA2, and pX330-sgRNA 3 with the targeting vector are shown in Table 6. [Table 6]
[0201] Example 7. Genotyping of humanized ACE2 mouse embryonic stem cells The cell lysate finally obtained in Example 6 is used as the PCR screening template for genotyping. PCR screening is performed using Phanta Max Super-Fidelity DNA Polymerase reagent (Novozan) according to the manufacturer's instructions. PCR analysis directs HDR with 5' and 3' homology arms inserted into the mouse Ace2 site. Since the ACE2 gene is located on the X chromosome and the mouse embryonic stem cells used are XY male, there is no occurrence of biallelic gene targeting. The upstream of the directional insertion primer was identified as being located within the puromycin resistance (Puro-F: aacctccccttctacgagc (SEQ ID NO: 28)), and the downstream of the primer paired with it was located outside the 3' homology arm (3arm-outR: tacagccaggatctggatgtcagc (SEQ ID NO: 29)). If the insertion position of the recombinant vector is correct, a band that should be 1504 bp in length should appear. At this time, the genomic sequence of the mouse embryonic stem cell Ace2 site is replaced with SEQ ID NO: 30. The PCR identification results are shown in Figure 9. A total of 14 clones were identified. Here, those marked with * are positive clones, and the PCR products are consistent with the sequencing results. The mouse embryonic stem cell clones with positive PCR results are successfully edited humanized mouse embryonic stem cell models, but the PGK-Puro screening marker is still retained, and both ends of PGK-Puro have a pair of frt sites in the same direction, so the safety issue caused by gene recombination can be solved by removing it using FLP recombinase. The method for deleting the PGK-Puro screening marker is as follows. Mouse embryonic stem cells with positive PCR results were cultured in a 6 cm dish and transfected with Nucleofector. TM Using a combination of IIs / 2b electroporator and a Mouse ES Cell Nucleofector® Kit (Lonza, VPH-1001) mouse embryonic stem cell electroporation kit, approximately 2 × 10 cells were electroporated using the A023 program. 6100 μL of embryonic stem cells are electroporated with the electroporation process containing pPGK-FLPo plasmid (Addgene, 13793). The transfected cells are seeded into six wells of a 6-well plate, and after 3 days, mouse embryonic stem cell clones are selected by using a glass needle to aspirate the monoclones and cultured in a 96-well plate. The next day, the monoclonals are digested and passaged, divided into two, one is screened with puromycin, and the other is cultured normally. If the PGK-Puro resistance screening marker is successfully deleted, the cells become intolerant and die after screening with puromycin. The corresponding clones that are intolerant to puromycin can be identified by PCR using the upstream primer (hACE2-F: tgatagtggttggcattgt (SEQ ID NO: 31)) and the downstream primer (3arm-outR: tacagccaggatctggatgtcagc (SEQ ID NO: 29)). After the successful deletion of the PGK-Puro screening marker, the PCR product is 1532bp long, and the PCR product before the deletion of PGK-Puro is 2863bp long. The genotyping results are shown in FIG. 9, where the gel electrophoresis band at 1500bp is the clone after the successful deletion of PGK-puro, and the band at 3000bp is the clone before the deletion. The corresponding puromycin-intolerant clone was finally successfully edited into a humanized ACE2-targeted mouse embryonic stem cell, that is, the mouse embryonic stem cell finally obtained a humanized ACE2 gene as shown in FIG. 10. Finally, the genomic sequence of the Ace2 site of the mouse embryonic stem cell after the deletion of PGK-puro was replaced with the sequence shown in SEQ ID NO:32.
[0202] Example 8: Creation of humanized ACE2 genetically modified mice 1. Inject 7.5 units of PMSG intraperitoneally into 4-10 week-old B6C3F1 female mice, inject hCG 48 hours later, and place them in a cage with CD1 male mice. The next morning, check the vaginal plugs of the female mice, select female mice with vaginal plugs, and record the corresponding insemination time of the female mice. 2. The next day, euthanize the pregnant mouse by cervical dislocation, disinfect the abdomen with 70% alcohol, cut the abdominal skin and muscle layer with dressing tweezers and ophthalmic scissors to open the abdominal cavity. Grasp the upper part of one uterine horn with tweezers, open a small opening in the membrane near the oviduct with scissors, cut the connection between the oviduct and the ovary, transfer the oviduct and the associated uterus to a 35 mm Petri dish, fix the fimbria side with tweezers, gently insert a flushing needle filled with M2 culture medium (Hogan, B. (1994). Manipulating the mouse embryo: a laboratory manual, 2nd edn (Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press).) into the fimbria, flush the oviduct with 0.1 mL of M2 culture medium, collect the flushed embryos in the oviduct, wash three times with M2, and collect E1.5 mouse 2-cell embryos. 3. The collected mouse embryos were placed in 0.3 M mannitol containing 0.1 mM MgSO4, 0.1 mM CaCl2, and 0.3% bovine serum albumin (Sigma-Aldrich Inc., St. Louis, MO), and subjected to direct current fusion at 60 V for 50 μs using a Cellfusion CF-150 / B electrofusion apparatus and a 250-um fusion tank (BLS Ltd., Budapest, Hungary) to obtain tetraploid embryos. The cells were placed in KSOM medium (Summers, MC, McGinnis, LK, Lawitts, JA, Raffin, M., and Biggers, JD (2000). IVF of mouse ova in a simplex optimized medium supplemented with amino acids. Hum Reprod 15, 1791-1801.) and cultured in a CO2 incubator for 24 hours, after which the zona pellucida was removed with acidic Tyrode's solution (Sigma-Aldrich, T1788), and the cells were aggregated with embryonic stem cells (humanized ACE2 mouse embryonic stem cells obtained in Example 6) to form mouse embryos (Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., and Roder, JC (1993). Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci USA 90, 8424-8428.) 4. Incubate overnight in a CO2 incubator and transplant into the uterus of a pseudopregnant mouse on day E2.5. After 17 days, the surrogate mouse is euthanized by cervical dislocation and then an abdominal operation is performed. The surrogate mouse that is alive and breathing is placed in a cage with lactating mice, and weaned after 21 days to obtain a genetically modified mouse derived entirely from embryonic stem cells, i.e., a humanized ACE2 gene-modified mouse (Figure 12). The corresponding medium composition is shown in Table 7. [Table 7]
[0203] Example 9. Identification of humanized ACE2 mouse expression Newborn humanized ACE2 mice and wild-type mice were dissected, and the lungs, kidneys, and intestines were removed, respectively, and lysed with Trizol, then RNA was extracted with a Cell / Tissue Total RNA Extraction Kit (Novozan, RC101-01), and inverted with HiScript II Q RT SuperMix for qPCR reagent (Novozan, R222-01). qPCR measurements (Novozan, Q321-02) were performed on the extracted tissue cDNA using hACE2-specific primers (hACE2-qF: TGATAGTGGTTGGCATTGT, hACE2-qR: CGATGGAGGCATAAGGATT) and mACE2-specific primers (mACE2-qF: GGTTGGCATCATCATCCT; mACE2-qR: GTCTGAGCATCATCACTGT). The results showed that humanized ACE2 mouse tissues specifically expressed hACE2, whereas wild-type mice did not express hACE2 (Figure 13), and mACE2 expression was lost in hACE2 mice (Figure 14). Furthermore, we collected intestinal tissues from hACE2 mice and wild-type ACE2 mice, respectively, and performed Western blotting experiments. We also performed sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with a human-specific ACE2 antibody (Abcam, ab 108209), which confirmed that hACE2 mice expressed hACE2 protein at the protein level (Figure 15).
[0204] Example 10: Method for producing mice (2-cell stage / Mg 2+ and Ca 2+ (Electrofusion liquid group with increased concentration) The mouse embryonic stem cells used in this example are puromycin-intolerant humanized ACE2-targeted mouse embryonic stem cells obtained in Examples 6 and 7 above. In a specific experiment, embryonic stem cells resuscitated from a liquid nitrogen frozen cell bank, particularly those with a passage number of p15 or less, are used and cultured and grown for 3 days in a 6 cm Petri dish. In this example, 12th generation embryonic stem cells were used. The solution compositions used in Example 1 and Example 10 are shown in Tables 8 to 10, respectively. [Table 8] [Table 9] [Table 10] 2. Mouse production (1) Inject 7.5 units of PMSG intraperitoneally into 4-10 week-old B6C3F1 female mice, inject hCG 48 hours later, and place them in a cage with CD1 male mice. Check the vaginal plugs of the female mice the next morning, select female mice with vaginal plugs, and record the corresponding insemination time of the female mice. (2) The next day, euthanize the pregnant mouse by cervical dislocation, disinfect the abdomen with 70% alcohol, cut the abdominal skin and muscle layer with dressing tweezers and ophthalmic scissors to open the abdominal cavity, grasp the upper part of one uterine horn with tweezers, open a small opening in the membrane near the oviduct with scissors, cut the connection between the oviduct and the ovary, transfer the oviduct and the attached uterus to a 35 mm Petri dish, fix the fimbria side with tweezers, gently insert a flushing needle filled with M2 culture medium (Hogan, 1994) into the fimbria, flush the oviduct with 0.1 mL of M2 culture medium, collect the flushed embryos with the oviduct, wash three times with M2, and collect E1.5 (1.5 days after fertilization) mouse 2-cell embryos. (3) The collected mouse 2-cell embryos are placed in the improved electrofusion solution (composition described in Table 8) and subjected to direct current electrofusion at 60 volts for 50 microseconds using a Cellfusion CF-150 / B electrofusion device and a fusion tank with a 250-micron electrode gap (BLS Ltd., Budapest, Hungary), thereby obtaining tetraploid embryos, and then the fused embryos are placed in KSOM medium (Summers et al., 2000) and cultured in a CO2 incubator for 15 hours. The results show that the fusion efficiency of the improved electrofusion solution reaches 100%. (4) Tetraploid embryos are grown to the 2-cell stage, the zona pellucida is removed with acidic Tyrode's solution, and the embryos are aggregated with mouse embryonic stem cells that have been digested with 0.25% trypsin, and then cultured for an additional 24 hours to form chimeric embryos. (5) Finally, the chimeric embryos are transferred to the uterus of pseudopregnant mice at 2.5 days of gestation, and newborn mice that have developed to full term are obtained 17 days later. Tetraploid embryos can efficiently form only extraembryonic tissues, such as the placenta, and thus newborn mice derived from chimeric embryos between tetraploid embryos and embryonic stem cells are entirely derived from embryonic stem cells. The flow chart for producing the mice of this example is shown in Figure 16. The results of the birth rate of the mice are shown in Figure 18. As can be seen from Figure 18, the survival rate of the mice produced by the method of Example 10 reached 25% (10 / 40).
[0205] Test Example 1 Except for the difference in obtaining embryonic stem cells from Example 10, the other operation steps are the same as those of Example 10. In this example, mouse embryonic stem cells are general embryonic stem cells that have not been genetically modified, and are obtained as follows: C57BL6 / J mouse embryonic stem cells are resuscitated from a liquid nitrogen frozen cell bank, and mouse embryonic stem cells at passage number p12 are used and cultured and grown in a 6 cm Petri dish for 3 days. The flow chart for producing mice is shown in Figure 16. The results of the birth rate of mice are shown in Figure 19. As can be seen from Figure 19, the survival rate of mice produced by the method of Test Example 1 reached 33.3% (48 / 144).
[0206] Example 11: Method for producing mice (2-cell stage / conventional fusion solution group) The mouse embryonic stem cells used in this example are puromycin-intolerant humanized ACE2-targeted mouse embryonic stem cells obtained in Examples 6 and 7 above. In a specific experiment, embryonic stem cells resuscitated from a liquid nitrogen frozen cell bank, particularly those with a passage number of p15 or less, are used and cultured and grown for 3 days in a 6 cm Petri dish. In this example, 12th generation embryonic stem cells were used. Here, the KSOM medium and M2 culture solution were the same as in Example 10. Inject 1.7.5 units of PMSG intraperitoneally into 4-10 week-old B6C3F1 female mice, inject hCG 48 hours later, and place them in a cage with CD1 male mice. Check the vaginal plugs of the female mice the next morning, select female mice with vaginal plugs, and record the corresponding insemination time of the female mice. 2. The next day, euthanize the pregnant mouse by cervical dislocation, disinfect the abdomen with 70% alcohol, cut the abdominal skin and muscle layer with dressing tweezers and ophthalmic scissors to open the abdominal cavity. Grasp the upper part of one uterine horn with tweezers, open a small opening in the membrane near the oviduct with scissors, cut the connection between the oviduct and the ovary, transfer the oviduct and the associated uterus to a 35 mm Petri dish, fix the fimbria side with tweezers, gently insert a flushing needle filled with M2 culture medium (Hogan, 1994) into the fimbria, flush the oviduct with 0.1 mL of M2 culture medium, collect the flushed embryos in the oviduct, wash three times with M2, and collect E1.5 mouse 2-cell embryos. 3. The collected mouse 2-cell embryos are placed in an electrofusion solution (composition shown in Table 11) and subjected to direct current electrofusion at 60 volts for 50 microseconds in a Cellfusion CF-150 / B electrofusion device and a fusion tank with a 250-micron electrode gap (BLS Ltd., Budapest, Hungary), thereby obtaining tetraploid embryos, and then the fused embryos are placed in KSOM medium (Summers et al., 2000) and cultured in a CO2 incubator for 24 hours. As a result, the fusion efficiency is 80-90%, and the electrofusion efficiency cannot reach 100%. 4. Tetraploid embryos are developed to the 2-cell stage, the zona pellucida is removed with acidic Tyrode's solution, and aggregated with mouse embryonic stem cells digested with 0.25% trypsin and cultured for an additional 24 hours to form chimeric embryos, or cultured for 48 hours to the blastocyst stage and embryonic stem cells are injected into the blastocyst cavity by micromanipulation (Nagy et al., 1993). 5. Finally, the chimeric embryos are transferred to the uterus of pseudopregnant mice on day 2.5 of gestation, and newborn mice that have developed to term are obtained 17 days later. Because tetraploid embryos can effectively form only extraembryonic tissues such as the placenta, newborn mice obtained from chimeric embryos between tetraploid embryos and embryonic stem cells are entirely derived from embryonic stem cells. [Table 11] The flow chart for producing mice is shown in Figure 16. The results of the birth rate of mice in this experiment are shown in Figure 18. As can be seen from Figure 18, the survival rate of mice was 14.2% (15 / 106).
[0207] Test Example 2 Except for the difference in obtaining embryonic stem cells from Example 11, the other procedures were the same as those in Example 11. In this example, mouse embryonic stem cells are general embryonic stem cells that have not been genetically modified, and are obtained according to the following method: C57BL6 / J mouse embryonic stem cells are resuscitated from a liquid nitrogen frozen cell bank, and mouse embryonic stem cells at passage number p12 are used and cultured and grown in a 6 cm Petri dish for 3 days. The flow chart for producing mice is shown in Figure 16. The results of the mouse birth rate are shown in Figure 19. As can be seen from Figure 19, the mouse survival rate was 21.1% (32 / 152).
[0208] Example 12: Method for producing mice (4-cell stage / Mg 2+ and Ca 2+ (Electrofusion liquid group with increased concentration) The mouse embryonic stem cells used in this example are puromycin-intolerant humanized ACE2-targeted mouse embryonic stem cells obtained in Examples 6 and 7 above. In a specific experiment, embryonic stem cells resuscitated from a liquid nitrogen frozen cell bank, particularly those with a passage number of p15 or less, are used and cultured and grown for 3 days in a 6 cm Petri dish. In this example, 12th generation embryonic stem cells were used. Here, the KSOM medium and M2 culture solution were the same as in Example 10. Inject 1.7.5 units of PMSG intraperitoneally into 4-10 week-old B6C3F1 female mice, inject hCG 48 hours later, and place them in a cage with CD1 male mice. Check the vaginal plugs of the female mice the next morning, select female mice with vaginal plugs, and record the corresponding insemination time of the female mice. 2. The next day, euthanize the pregnant mouse by cervical dislocation, disinfect the abdomen with 70% alcohol, cut the abdominal skin and muscle layer with dressing tweezers and ophthalmic scissors to open the abdominal cavity. Grasp the upper part of one uterine horn with tweezers, open a small opening in the membrane near the oviduct with scissors, cut the connection between the oviduct and the ovary, transfer the oviduct and the associated uterus to a 35 mm Petri dish, fix the fimbria side with tweezers, gently insert a flushing needle filled with M2 culture medium (Hogan, 1994) into the fimbria, flush the oviduct with 0.1 mL of M2 culture medium, collect the flushed embryos in the oviduct, wash three times with M2, and collect E1.5 mouse 2-cell embryos. 3. The collected mouse 2-cell embryos are placed in an electrofusion solution (composition shown in Table 12) and subjected to direct current electrofusion at 60 volts for 50 microseconds using a Cellfusion CF-150 / B electrofusion device and a fusion tank with a 250-micron electrode gap (BLS Ltd., Budapest, Hungary), thereby obtaining tetraploid embryos, and then the fused embryos are placed in KSOM medium (Summers et al., 2000) and cultured in a CO2 incubator for 24 hours. The results show that the fusion efficiency of the improved electrofusion solution reaches 100%. 4. Tetraploid embryos are developed to the 4-cell stage, the zona pellucida is removed with acidic Tyrode's solution, and aggregated with mouse embryonic stem cells digested with 0.25% trypsin and cultured for an additional 24 hours to form chimeric embryos, or cultured for 48 hours to the blastocyst stage and embryonic stem cells are injected into the blastocyst cavity by micromanipulation (Nagy et al., 1993). 5. Finally, the chimeric embryos are transferred to the uterus of pseudopregnant mice on day 2.5 of gestation, and newborn mice that have developed to term are obtained 17 days later. Because tetraploid embryos can effectively form only extraembryonic tissues such as the placenta, newborn mice obtained from chimeric embryos between tetraploid embryos and embryonic stem cells are entirely derived from embryonic stem cells. [Table 12] The flow chart for manufacturing the mouse is shown in FIG. The results of the mouse birth rate in this experiment are shown in Figure 18. As can be seen from Figure 18, the mouse survival rate was 2.5% (3 / 121).
[0209] Test Example 3 Except for the difference in obtaining embryonic stem cells from Example 12, the other procedures were the same as those in Example 12. In this example, mouse embryonic stem cells are general embryonic stem cells that have not been genetically modified, and are obtained as follows: C57BL6 / J mouse embryonic stem cells are resuscitated from a liquid nitrogen frozen cell bank, and mouse embryonic stem cells at passage number p12 are used and cultured and grown in a 6 cm Petri dish for 3 days. The flow chart for producing mice is shown in Figure 17. The results of the birth rate of mice are shown in Figure 19. As can be seen from Figure 19, the survival rate of mice was 7.5% (9 / 120).
[0210] Example 13: Mouse production method (4-cell stage / conventional fusion solution group) The mouse embryonic stem cells used in this example are puromycin-intolerant humanized ACE2-targeted mouse embryonic stem cells obtained in Examples 6 and 7 above. In a specific experiment, embryonic stem cells resuscitated from a liquid nitrogen frozen cell bank, particularly those with a passage number of p15 or less, are used and cultured and grown in a 6 cm Petri dish for 3 days. In this example, 12th generation embryonic stem cells were used. Here, the KSOM medium and M2 culture medium are the same as those in Example 10. Inject 1.7.5 units of PMSG intraperitoneally into 4-10 week-old B6C3F1 female mice, inject hCG 48 hours later, and place them in a cage with CD1 male mice. Check the vaginal plugs of the female mice the next morning, select female mice with vaginal plugs, and record the corresponding insemination time of the female mice. 2. The next day, euthanize the pregnant mouse by cervical dislocation, disinfect the abdomen with 70% alcohol, cut the abdominal skin and muscle layer with dressing tweezers and ophthalmic scissors to open the abdominal cavity. Grasp the upper part of one uterine horn with tweezers, open a small opening in the membrane near the oviduct with scissors, cut the connection between the oviduct and the ovary, transfer the oviduct and the associated uterus to a 35 mm Petri dish, fix the fimbria side with tweezers, gently insert a flushing needle filled with M2 culture medium (Hogan, 1994) into the fimbria, flush the oviduct with 0.1 mL of M2 culture medium, collect the flushed embryos in the oviduct, wash three times with M2, and collect E1.5 mouse 2-cell embryos. 3. The collected mouse 2-cell embryos were placed in electrofusion solution (composition shown in Table 13) and subjected to direct current electrofusion at 60 volts for 50 microseconds in a Cellfusion CF-150 / B electrofusion device and a fusion tank with a 250-micron electrode gap (BLS Ltd., Budapest, Hungary), thereby obtaining tetraploid embryos, after which the fused embryos were placed in KSOM medium (Summers et al., 2000) and cultured in a CO2 incubator for 24 hours. The electrofusion efficiency was 80-90%. 4. Tetraploid embryos are developed to the 4-cell stage, the zona pellucida is removed with acidic Tyrode's solution, and aggregated with mouse embryonic stem cells digested with 0.25% trypsin and cultured for an additional 24 hours to form chimeric embryos, or cultured for 48 hours to the blastocyst stage and embryonic stem cells are injected into the blastocyst cavity by micromanipulation (Nagy et al., 1993). 5. Finally, the chimeric embryos are transferred to the uterus of pseudopregnant mice on day 2.5 of gestation, and newborn mice that have developed to term are obtained 17 days later. Because tetraploid embryos can effectively form only extraembryonic tissues such as the placenta, newborn mice obtained from chimeric embryos between tetraploid embryos and embryonic stem cells are entirely derived from embryonic stem cells. [Table 13] The process and results of producing mice in Example 5 are shown in Figure 17. As can be seen from Figure 17, the efficiency of mouse production is very low. Furthermore, the results of the mouse birth rate are shown in Figure 18. As can be seen from Figure 18, the mouse survival rate was only 0.3% (1 / 350).
[0211] Test Example 4 Except for the difference in obtaining embryonic stem cells from Example 13, the other procedures were the same as those in Example 13. In this example, mouse embryonic stem cells are general embryonic stem cells that have not been genetically modified, and are obtained according to the following method: C57BL6 / J mouse embryonic stem cells are resuscitated from a liquid nitrogen frozen cell bank, and mouse embryonic stem cells at passage number p12 are used and cultured and grown in a 6 cm Petri dish for 3 days. The flow chart for producing mice is shown in Figure 17. The results of the birth rate of mice are shown in Figure 19. As can be seen from Figure 19, the survival rate of mice was only 2.5% (4 / 163).
Claims
1. A method for producing a non-human chimeric embryo, said method comprising aggregating a non-human tetraploid embryo with a non-human embryonic stem cell to form a new reconstituted embryo or chimeric embryo, said tetraploid embryo being a tetraploid embryo at the 2-cell stage; The method uses tetraploid compensation or tetraploid embryo complementation, The method (1) obtaining a two-cell embryo of a non-human animal; (2) placing the 2-cell embryos described in step (1) in a fusion solution and fusing them to obtain tetraploid embryos; (3) placing the tetraploid embryos in step (2) in a medium and culturing them; (4) aggregating the tetraploid embryos developed to the 2-cell stage in step (3) with non-human embryonic stem cells to form chimeric embryos; The method comprises the steps of: 0.27 M mannitol, 0.2 mM MgSO 4 , 0.2 mM CaCl 2 and an electrofusion solution containing 3 mg / mL bovine serum albumin; In the step (3), the tetraploid embryos are cultured for about 8 to 24 hours, and the medium in the step (3) is KSOM medium.
2. 1. A method for producing a non-human animal, the method comprising aggregating a non-human tetraploid embryo with a non-human embryonic stem cell to form a new reconstituted embryo or a chimeric embryo, the tetraploid embryo being a 2-cell stage tetraploid embryo; The method uses tetraploid compensation or tetraploid embryo complementation, The method (1) obtaining a two-cell embryo of a non-human animal; (2) placing the 2-cell embryos described in step (1) in a fusion solution and fusing them to obtain tetraploid embryos; (3) placing the tetraploid embryos in step (2) in a medium and culturing them; (4) aggregating the tetraploid embryos developed to the 2-cell stage in step (3) with non-human embryonic stem cells to form chimeric embryos; (5) injecting the chimeric embryo into an animal; The method comprises the steps of: 0.27 M mannitol, 0.2 mM MgSO 4 , 0.2 mM CaCl 2 and an electrofusion solution containing 3 mg / mL bovine serum albumin; In the step (3), the tetraploid embryos are cultured for about 8 to 24 hours, and the medium in the step (3) is KSOM medium.
3. 3. The method of claim 2, wherein the animal is selected from pigs, rats, mice, hamsters, rabbits, pigs, cows, deer, sheep, goats, chickens, cats, horses, dogs, orangutans, and monkeys.
4. The method of claim 2, wherein the animal is selected from a mouse.
5. The embryonic stem cell is prepared by using a targeting vector comprising a 5' homology arm sequence, a human ACE2 gene fragment, an SV40 polyA sequence and a 3' homology arm linked together; The method of claim 1 or 2, wherein the 5' homology arm comprises the sequence shown in SEQ ID NO: 15, the CDS region of the ACE2 gene comprises the sequence shown in SEQ ID NO: 12, the SV40 polyA comprises the sequence shown in SEQ ID NO: 14, and the 3' homology arm comprises the sequence shown in SEQ ID NO:
16.
6. the 5' homology arm sequence, the human ACE2 gene fragment and the SV40 polyA sequence are ligated and inserted into the targeting vector using a primer combination; The primer combination is an upstream primer represented by SEQ ID NO: 19 and a downstream primer represented by SEQ ID NO: 20; an upstream primer represented by SEQ ID NO: 21 and a downstream primer represented by SEQ ID NO: 22; an upstream primer represented by SEQ ID NO: 23 and a downstream primer represented by SEQ ID NO: 24, and An upstream primer represented by SEQ ID NO: 25 and a downstream primer represented by SEQ ID NO: 26 The method of claim 5 , comprising:
7. The method of claim 5, wherein the targeting vector is used to insert the CDS sequence of a human-derived ACE2 gene into the promoter and 5'UTR region sequence of an animal gene so as to initiate expression of a human gene of interest using an animal gene of interest promoter, and the SV40 PolyA is positioned downstream of the CDS region.
8. 6. The method of claim 5, wherein the targeting vector further comprises a screening marker PGK-Puro having the sequence shown in SEQ ID NO: 17, and / or the targeting vector further comprises an Frt site having the sequence shown in SEQ ID NO:
18.
9. The method according to claim 5, wherein the sequence of each sequence fragment of the targeting vector is ligated in the order of 5' homology arm sequence, human-derived ACE2 gene fragment, SV40 polyA sequence, frt sequence, PGK-Puro sequence, frt sequence and 3' homology arm sequence.
10. The method comprises: (1) producing the targeting vector; (2) introducing the targeting vector and the sgRNA-linked vector into a non-human embryonic stem cell derived from an animal; (3) culturing the embryonic stem cells in step (2) to obtain a cell line or cell line; 10. The method of claim 9, wherein the sgRNA is selected from the group of sgRNAs having the sequence shown in SEQ ID NO: 1 or SEQ ID NO:
2.
11. A non-human animal produced by the method of claim 2.
12. A non-human animal or its progeny obtained by the method according to claim 2, (a) for use in producing human antibodies; (b) to serve as models for pharmacological, immunological, microbiological and medical research; (c) for the study of pathogenesis and / or the development of new diagnostic and / or therapeutic strategies by producing and utilising animal experimental disease models; or (d) Methods used to validate, evaluate or study ACE2 gene function, ACE2 antibodies, screening of drugs against ACE2 targets and their efficacy.
Citation Information
Patent Citations
Electric fusion of yeast
JP1989300896A
Method for producing nucleus-transplanted egg, nucleus- transplanted egg obtained by the method, clonal individual obtained by breeding the nucleus- transplanted egg and method for producing the clonal individual
JP2002320428A
Method for fusing dendritic cell with diseased tissue cell, especially with tumor cell, and medium used in the same or similar method
JP2002325570A
Process for developing mammal with definite genetic feature
JP2006296440A
Es cell strain, chimera mouse, knockout mouse, and method for producing them
JP2007181418A
